

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
<b>A</b>	<b>ALIMENTARY TRACT AND METABOLISM</b>	<b>292,86</b>	<b>4</b>	<b>-11</b>	<b>298 491</b>	<b>7</b>	<b>-16</b>
A01	STOMATOLOGICAL PREPARATIONS	2,80	7	-53	1 910	7	-21
A01A	STOMATOLOGICAL PREPARATIONS	2,80	7	-53	1 910	7	-21
A01AA	Caries prophylactic agents	0,45	10	-89	619	12	-54
A01AA01	sodium fluoride	0,45	10	-89	498	15	-54
A01AA03	olaflur	-	-	-	50	1	4
A01AA51	sodium fluoride, combinations	-	-	-	71	1	-65
A01AB	Antiinfectives for local oral treatment	2,31	7	15	1 052	6	12
A01AB03	chlorhexidine	2,09	7	17	825	7	17
A01AB11	various	0,22	0	-5	227	0	-5
A01AB22	doxycycline	-	-	-	0	100	-
A01AC	Corticosteroids for local oral treatment	-	-	-	135	1	-6
A01AC01	triamcinolone	-	-	-	135	1	-6
A01AD	Other agents for local oral treatment	0,04	0	-	104	0	-
A01AD02	benzydamine	0,04	0	-	104	0	-
A02	DRUGS FOR ACID RELATED DISORDERS	69,32	3	-7	35 102	5	-17
A02A	ANTACIDS	2,20	1	-4	3 357	1	-1
A02AA	Magnesium compounds	0,08	22	-23	172	22	11
A02AA04	magnesium hydroxide	0,08	22	-23	172	22	11
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	2,12	0	-3	3 185	0	-1
A02AD01	ordinary salt combinations	2,12	0	-3	3 185	0	-1
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	67,12	3	-7	31 746	5	-18
A02BA	H2-receptor antagonists	1,10	4	0	1 008	7	-4
A02BA02	ranitidine	0,99	3	0	621	3	-2
A02BA03	famotidine	0,11	10	-6	387	14	-5
A02BB	Prostaglandins	0,03	71	22	64	71	22
A02BB01	misoprostol	0,03	71	22	64	71	22
A02BC	Proton pump inhibitors	64,75	3	-8	28 167	5	-20
A02BC01	omeprazole	9,29	2	-6	2 701	3	-15
A02BC02	pantoprazole	33,31	5	4	11 337	8	-16

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A02BC03	lansoprazole	5,82	0	-10	2 655	0	-16
A02BC04	rabeprazole	1,37	0	8	760	0	11
A02BC05	esomeprazole	14,96	2	-26	10 714	3	-27
A02BD	Combinations for eradication of Helicobacter pylori	0,03	0	-4	309	0	-4
A02BD03	lansoprazole, metronidazole and amoxicillin	0,01	0	-3	72	0	-3
A02BD07	lansoprazole, amoxicillin and clarithromycin	0,02	0	-4	238	0	-4
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	1,20	8	1	2 197	7	6
A02BX02	sucralfate	0,26	21	6	411	21	6
A02BX13	alginic acid	0,94	4	-1	1 786	4	6
A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	2,65	10	4	5 490	44	-5
A03A	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	1,02	7	10	1 772	18	-2
A03AB	Synthetic anticholinergics, quaternary ammonium compounds	0,04	90	2	307	90	2
A03AB02	glycopyrronium bromide	0,04	90	2	307	90	2
A03AX	Other drugs for functional gastrointestinal disorders	0,98	4	11	1 464	3	-3
A03AX13	silicones	0,98	4	11	1 464	3	-3
A03B	BELLADONNA AND DERIVATIVES, PLAIN	0,06	92	-22	546	92	-3
A03BA	Belladonna alkaloids, tertiary amines	0,05	91	-10	456	92	7
A03BA01	atropine	0,05	91	-10	456	92	7
A03BB	Belladonna alkaloids semisynthetic, quaternary ammonium compounds	0,00	95	-73	90	95	-35
A03BB01	butylscopolamine	0,00	95	-73	90	95	-35
A03C	ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS	0,20	1	-16	194	1	-16
A03CA	Synthetic anticholinergic agents in combination with psycholeptics	0,20	1	-16	194	1	-16
A03CA02	clidinium and psycholeptics	0,20	1	-16	194	1	-16
A03D	ANTISPASMODICS IN COMBINATION WITH ANALGESICS	0,38	8	20	2 577	57	-4
A03DA	Synthetic anticholinergic agents in combination with analgesics	0,38	8	20	2 577	57	-4

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A03DA02	pitofenone and analgesics	0,38	8	20	2 577	57	-4
A03F	PROPULSIVES	0,99	11	-1	401	33	-13
A03FA	Propulsives	0,99	11	-1	401	33	-13
A03FA01	metoclopramide	0,99	11	-1	401	33	-13
A04	ANTIEMETICS AND ANTINAUSEANTS	0,25	48	-9	3 729	46	-32
A04A	ANTIEMETICS AND ANTINAUSEANTS	0,25	48	-9	3 729	46	-32
A04AA	Serotonin (5HT3) antagonists	0,18	56	1	2 783	46	-10
A04AA01	ondansetron	0,15	51	3	1 048	44	-10
A04AA02	granisetron	0,03	68	-12	487	67	-45
A04AA05	palonosetron	0,01	97	15	317	99	-40
A04AA55	palonosetron, combinations	-	-	-	930	20	84
A04AD	Other antiemetics	0,07	29	-28	947	44	-61
A04AD01	scopolamine	0,06	27	7	299	27	7
A04AD12	aprepitant	0,01	40	-71	633	52	-70
A04AD14	rolapitant	0,00	52	-	14	66	291
A05	BILE AND LIVER THERAPY	0,83	2	6	2 101	3	-2
A05A	BILE THERAPY	0,83	2	6	2 101	3	-2
A05AA	Bile acids and derivatives	0,83	2	6	2 101	3	-2
A05AA02	ursodeoxycholic acid	0,83	2	6	2 101	3	-2
A06	DRUGS FOR CONSTIPATION	45,41	10	1	25 596	13	0
A06A	DRUGS FOR CONSTIPATION	45,41	10	1	25 596	13	0
A06AB	Contact laxatives	6,29	7	-5	3 788	9	-3
A06AB02	bisacodyl	0,97	5	-10	385	6	-10
A06AB06	senna glycosides	0,29	0	-7	119	0	-7
A06AB08	sodium picosulfate	5,02	8	-4	2 653	7	-3
A06AB56	senna glycosides, combinations	-	-	-	183	0	-9
A06AB58	sodium picosulfate, combinations	0,00	29	5	448	29	5
A06AC	Bulk-forming laxatives	9,96	0	1	4 883	2	2
A06AC01	ispaghula (psylla seeds)	9,34	0	2	4 640	2	3
A06AC51	ispaghula, combinations	0,62	2	-6	244	2	-6
A06AD	Osmotically acting laxatives	27,62	14	3	13 670	15	-1
A06AD11	lactulose	14,19	11	-5	2 867	11	-5
A06AD15	macrogol	13,43	16	13	8 940	15	7
A06AD17	sodium phosphate	-	-	-	51	17	-31

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A06AD65	macrogol, combinations	-	-	-	1 813	21	-24
A06AG	Enemas	1,43	18	-1	2 636	23	-2
A06AG02	bisacodyl	0,28	41	-7	466	40	-7
A06AG10	docusate sodium, incl. combinations	0,06	54	-9	614	51	-7
A06AG11	laurilsulfate, incl. combinations	1,09	10	1	1 557	7	1
A06AH	Peripheral opioid receptor antagonists	0,07	38	58	443	51	25
A06AH01	methylnaltrexone bromide	0,00	93	-18	119	93	-18
A06AH03	naloxegol	0,07	35	67	324	36	55
A06AX	Other drugs for constipation	0,04	12	14	175	14	11
A06AX04	linaclotide	0,02	2	2	77	2	-8
A06AX05	prucalopride	0,02	24	31	98	23	31
A07	ANTIDIARRHEALS, INTESTINAL	13,43	2	-1	28 852	5	-1
	ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS						
A07A	INTESTINAL ANTIINFECTIVES	0,08	28	17	1 738	44	-2
A07AA	Antibiotics	0,08	28	17	1 738	44	-2
A07AA02	nystatin	0,03	26	2 189	292	27	1 287
A07AA09	vancomycin	0,01	56	0	670	56	0
A07AA11	rifaximin	0,05	25	-23	545	25	-23
A07AA12	fidaxomicin	0,00	77	-39	231	77	-39
A07B	INTESTINAL ADSORBENTS	0,14	48	-7	691	48	-5
A07BA	Charcoal preparations	0,14	48	-7	691	48	-5
A07BA01	medicinal charcoal	0,14	48	-7	691	48	-5
A07C	ELECTROLYTES WITH CARBOHYDRATES	0,01	6	-7	269	6	-1
A07CA	Oral rehydration salt formulations	0,01	6	-7	269	6	-1
A07D	ANTIPROPULSIVES	1,31	2	-1	4 284	1	2
A07DA	Antipropulsives	1,31	2	-1	4 284	1	2
A07DA03	loperamide	1,31	2	-1	3 215	1	-1
A07DA06	eluxadoline	0,00	0	-	19	1	51
A07DA53	loperamide, combinations	-	-	-	1 050	0	12
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS	10,40	1	2	17 076	1	3
A07EA	Corticosteroids acting locally	0,30	3	-5	1 671	3	5
A07EA02	hydrocortisone	0,00	0	-100	0	0	-100
A07EA06	budesonide	0,30	3	9	1 671	3	12
A07EB	Antiallergic agents, excl.corticosteroids	0,00	17	-107	-1	17	-107

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A07EB01	cromoglicic acid	0,00	17	-107	-1	17	-107
A07EC	Aminosalicylic acid and similar agents	10,11	1	2	15 405	1	3
A07EC01	sulfasalazine	3,24	1	-1	2 904	1	-1
A07EC02	mesalazine	6,85	1	4	12 478	1	4
A07EC03	olsalazine	0,01	1	-19	23	1	-19
A07F	ANTIDIARRHEAL MICROORGANISMS	1,48	6	-17	4 373	6	-17
A07FA	Antidiarrheal microorganisms	1,48	6	-17	4 373	6	-17
A07FA01	lactic acid producing organisms	0,05	1	-28	72	1	-27
A07FA02	saccharomyces boulardii	1,43	6	-16	4 301	6	-17
A07X	OTHER ANTIDIARRHEALS	-	-	-	422	4	124
A07XA	Other antidiarrheals	-	-	-	422	4	124
A07XA04	racecadotril	-	-	-	422	4	124
A08	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS	0,09	1	-14	558	0	59
A08A	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS	0,09	1	-14	558	0	59
A08AA	Centrally acting antiobesity products	-	-	-	266	0	3 450
A08AA62	bupropion and naltrexone	-	-	-	266	0	3 450
A08AB	Peripherally acting antiobesity products	0,09	1	-14	292	1	-15
A08AB01	orlistat	0,09	1	-14	292	1	-15
A09	DIGESTIVES, INCL. ENZYMES	0,92	4	-3	2 613	4	7
A09A	DIGESTIVES, INCL. ENZYMES	0,92	4	-3	2 613	4	7
A09AA	Enzyme preparations	0,92	4	-3	2 613	4	7
A09AA02	multienzymes (lipase, protease etc.)	0,92	4	-3	2 613	4	7
A10	DRUGS USED IN DIABETES	95,76	2	-21	154 780	2	-24
A10A	INSULINS AND ANALOGUES	32,14	3	-26	63 808	3	-27
A10AB	Insulins and analogues for injection, fast-acting	10,29	3	-16	16 240	3	-17
A10AB01	insulin (human)	0,09	37	-16	108	37	-16
A10AB04	insulin lispro	1,87	2	-38	2 896	2	-39
A10AB05	insulin aspart	7,82	3	-9	12 413	3	-9
A10AB06	insulin glulisine	0,51	2	-15	823	2	-15
A10AC	Insulins and analogues, intermediate-acting	0,72	10	-11	1 018	10	-10
A10AC01	insulin (human)	0,72	10	-11	1 018	10	-10
A10AD	Insulins and analogues, intermediate-acting combined with fast-acting	0,43	5	-20	743	5	-20

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A10AD01	insulin (human)	-	-	-100	0	-	-100
A10AD04	insulin lispro	0,03	4	-58	49	4	-58
A10AD05	insulin aspart	0,41	5	-14	694	5	-14
A10AE	Insulins and analogues, long-acting	20,68	2	-31	45 807	2	-31
A10AE04	insulin glargine	13,69	2	-40	28 682	2	-41
A10AE05	insulin detemir	6,60	2	-3	15 962	2	-4
A10AE06	insulin degludec	0,40	2	195	1 162	2	91
A10AE54	insulin glargine and lixisenatide	-	-	-	0	0	-
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	63,63	1	-18	90 972	1	-21
A10BA	Biguanides	32,16	1	-10	11 241	1	-8
A10BA02	metformin	32,16	1	-10	11 241	1	-8
A10BB	Sulfonylureas	1,41	1	-20	138	1	-20
A10BB07	glipizide	-	-	-100	0	-	-100
A10BB12	glimepiride	1,41	1	-20	138	1	-19
A10BD	Combinations of oral blood glucose lowering drugs	5,87	0	-41	13 744	0	-40
A10BD05	metformin and pioglitazone	0,01	0	-94	17	0	-94
A10BD07	metformin and sitagliptin	4,36	1	-50	9 669	1	-50
A10BD08	metformin and vildagliptin	0,63	0	-5	1 477	0	-6
A10BD09	pioglitazone and alogliptin	0,01	0	-1	22	0	-2
A10BD10	metformin and saxagliptin	0,02	0	-7	45	0	-7
A10BD11	metformin and linagliptin	0,20	0	8	463	0	7
A10BD13	metformin and alogliptin	0,01	0	0	31	0	-1
A10BD15	metformin and dapagliflozin	0,33	0	47	776	0	46
A10BD19	linagliptin and empagliflozin	-	-	-	141	0	-
A10BD20	metformin and empagliflozin	0,29	0	-	1 083	0	99
A10BD21	saxagliptin and dapagliflozin	-	-	-	20	0	1 488
A10BD24	sitagliptin and ertugliflozin	-	-	-	0	0	-
A10BG	Thiazolidinediones	0,56	1	-6	811	1	-3
A10BG03	pioglitazone	0,56	1	-6	811	1	-3
A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors	13,47	2	-39	30 050	2	-40
A10BH01	sitagliptin	8,21	2	-52	18 649	2	-53
A10BH02	vildagliptin	1,08	2	-11	2 317	2	-12
A10BH03	saxagliptin	0,06	1	-15	144	1	-14

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A10BH04	alogliptin	0,04	1	-9	85	1	-9
A10BH05	linagliptin	4,08	3	13	8 855	4	13
A10BJ	Glucagon-like peptide-1 (GLP-1) analogues	3,31	1	10	18 060	1	7
A10BJ01	exenatide	0,54	1	-12	3 030	1	-13
A10BJ02	liraglutide	2,39	1	17	13 128	1	13
A10BJ03	lixisenatide	0,00	1	33	27	1	29
A10BJ05	dulaglutide	0,37	1	9	1 876	1	8
A10BK	Sodium-glucose co-transporter 2 (SGLT2) inhibitors	6,67	1	39	16 879	1	36
A10BK01	dapagliflozin	2,67	1	21	6 267	1	21
A10BK03	empagliflozin	4,00	1	54	10 609	1	46
A10BK04	ertugliflozin	0,00	2	-	2	2	-
A10BX	Other blood glucose lowering drugs, excl. insulins	0,18	1	-2	50	2	-47
A10BX01	guar gum	-	-	-	4	1	-94
A10BX02	repaglinide	0,18	1	-2	46	2	40
A11	VITAMINS	21,00	4	-9	9 322	13	-4
A11C	VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO	0,48	5	9	934	4	7
A11CC	Vitamin D and analogues	0,48	5	9	934	4	7
A11CC01	ergocalciferol (vitamin D2)	-	-	-	11	2	-17
A11CC02	dihydrotachysterol	0,06	3	11	78	3	11
A11CC03	alfacalcidol	0,42	5	9	409	8	10
A11CC05	colecalfiferol (vitamin D3)	-	-	-	436	1	3
A11D	VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12	5,25	12	-8	2 262	49	-3
A11DA	Vitamin B1, plain	0,49	99	1	1 073	99	4
A11DA01	thiamine (vit B1)	0,49	99	1	1 073	99	4
A11DB	Vitamin B1 in comb. with vitamin B6 and/or vitamin B12	4,75	3	-9	1 189	4	-9
A11E	VITAMIN B-COMPLEX, INCL. COMBINATIONS	12,81	1	-5	5 744	1	-5
A11EA	Vitamin B-complex	2,74	4	-1	1 033	4	-1
A11EX	Vitamin B-complex, other combinations	10,07	0	-7	4 711	0	-6
A11G	ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS	2,19	1	-28	146	1	-28

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A11GA	Ascorbic acid (vit C), plain	2,19	1	-28	146	1	-28
A11GA01	ascorbic acid (vit C)	2,19	1	-28	146	1	-28
A11H	OTHER PLAIN VITAMIN PREPARATIONS	0,27	7	-18	236	3	-8
A11HA	Other plain vitamin preparations	0,27	7	-18	236	3	-8
A11HA02	pyridoxine (vit B6)	0,15	13	-9	48	13	-9
A11HA03	tocopherol (vit E)	0,12	1	-27	27	1	-27
A11HA30	dexpanthenol	-	-	-	161	1	-4
A12	MINERAL SUPPLEMENTS	40,35	3	4	15 792	5	5
A12A	CALCIUM	34,55	3	3	10 806	2	3
A12AA	Calcium	1,10	2	9	815	2	6
A12AA02	calcium glubionate	-	-	-100	0	-	-100
A12AA04	calcium carbonate	1,10	2	10	809	2	9
A12AA06	calcium lactate gluconate	0,00	9	-74	6	9	-73
A12AX	Calcium, combinations with vitamin D and/or other drugs	33,45	3	3	9 991	2	3
A12B	POTASSIUM	5,70	8	5	4 909	9	8
A12BA	Potassium	5,70	8	5	4 909	9	8
A12BA01	potassium chloride	5,65	8	5	4 780	9	8
A12BA51	potassium chloride, combinations	0,05	3	4	130	3	12
A12C	OTHER MINERAL SUPPLEMENTS	0,10	47	39	77	47	39
A12CA	Sodium	0,10	47	39	77	47	39
A12CA01	sodium chloride	0,10	47	39	77	47	39
A14	ANABOLIC AGENTS FOR SYSTEMIC USE	0,02	25	-18	18	25	-18
A14A	ANABOLIC STEROIDS	0,02	25	-18	18	25	-18
A14AB	Estren derivatives	0,02	25	-18	18	25	-18
A14AB01	nandrolone	0,02	25	-18	18	25	-18
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	0,02	44	-3	12 627	42	2
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	0,02	44	-3	12 627	42	2
A16AB	Enzymes	0,01	58	6	11 108	47	7
A16AB03	agalsidase alfa	0,00	60	2	1 837	60	1
A16AB04	agalsidase beta	0,01	43	7	8 008	42	6
A16AB05	laronidase	0,00	100	21	311	100	21



## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
A16AB07	alglucosidase alfa	0,00	100	4	356	100	4
A16AB09	idursulfase	-	-	-	3	100	-96
A16AB10	velaglucerase alfa	0,00	6	63	592	6	62
A16AX	Various alimentary tract and metabolism products	0,01	6	-21	1 519	8	-27
A16AX03	sodium phenylbutyrate	0,00	4	-26	272	4	-26
A16AX04	nitisinone	0,00	0	13	529	0	0
A16AX06	miglustat	0,00	6	-73	304	6	-74
A16AX08	teduglutide	0,00	100	100	38	100	100
A16AX09	glycerol phenylbutyrate	-	-	-	28	26	-
A16AX10	eliglustat	0,00	0	-	208	0	-
A16AX14	migalastat	0,00	0	-	100	0	-
A16AX15	telotristat	0,00	100	-	40	100	-
<b>B</b>	<b>BLOOD AND BLOOD FORMING ORGANS</b>	<b>135,64</b>	<b>4</b>	<b>-5</b>	<b>238 033</b>	<b>29</b>	<b>-2</b>
B01	ANTITHROMBOTIC AGENTS	115,10	4	-4	116 488	17	16
B01A	ANTITHROMBOTIC AGENTS	115,10	4	-4	116 488	17	16
B01AA	Vitamin K antagonists	12,64	2	-14	2 896	2	-15
B01AA03	warfarin	12,64	2	-14	2 896	2	-15
B01AB	Heparin group	6,86	36	-4	25 144	40	-1
B01AB01	heparin	0,08	94	-1	810	94	-8
B01AB02	antithrombin	0,00	100	50	451	100	50
B01AB04	dalteparin	0,55	3	-26	1 387	3	-28
B01AB05	enoxaparin	5,29	40	-7	16 307	41	-7
B01AB09	danaparoid	0,00	74	-25	200	74	-25
B01AB10	tinzaparin	0,94	26	45	5 989	33	36
B01AC	Platelet aggregation inhibitors excl. heparin	81,55	2	-8	20 059	7	-6
B01AC04	clopidogrel	8,38	3	3	1 372	22	-9
B01AC06	acetylsalicylic acid	67,14	1	-10	7 731	1	-12
B01AC07	dipyridamole	0,45	2	-16	391	2	-15
B01AC11	iloprost	0,00	67	-12	304	41	-15
B01AC13	abciximab	0,00	100	-51	69	100	-50
B01AC16	eptifibatide	0,00	100	-48	89	100	-48
B01AC17	tirofiban	0,00	100	-23	51	100	-23
B01AC21	treprostinil	0,00	6	21	2 015	7	21
B01AC22	prasugrel	0,02	24	-48	82	24	-48

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
B01AC24	ticagrelor	0,80	4	7	3 301	4	7
B01AC25	cangrelor	0,00	100	18	137	100	18
B01AC27	selexipag	0,00	6	-5	543	12	-23
B01AC30	combinations	4,75	2	-5	3 975	2	-5
B01AD	Enzymes	0,00	100	-35	4 967	100	-32
B01AD02	alteplase	0,00	100	-39	4 046	100	-34
B01AD07	reteplase	0,00	100	-50	252	100	-50
B01AD11	tenecteplase	0,00	99	-3	669	99	-3
B01AE	Direct thrombin inhibitors	2,46	2	19	11 284	5	11
B01AE03	argatroban	0,00	100	-32	52	100	-32
B01AE06	bivalirudin	0,00	100	-26	211	100	-46
B01AE07	dabigatran etexilate	2,46	2	19	11 021	2	14
B01AF	Direct factor Xa inhibitors	11,56	3	66	51 214	3	59
B01AF01	rivaroxaban	5,99	2	42	25 299	3	34
B01AF02	apixaban	5,25	3	98	24 362	4	90
B01AF03	edoxaban	0,33	2	252	1 554	3	239
B01AX	Other antithrombotic agents	0,02	13	3	923	83	-1
B01AX01	defibrotide	0,00	99	-1	750	99	-1
B01AX05	fondaparinux	0,02	13	3	174	14	0
B02	ANTIHEMORRHAGICS	0,32	23	-16	58 389	28	-24
B02A	ANTIFIBRINOLYTICS	0,25	20	10	1 789	73	9
B02AA	Amino acids	0,24	20	10	1 680	71	6
B02AA02	tranexamic acid	0,24	20	10	1 680	71	6
B02AB	Proteinase inhibitors	0,00	100	195	109	100	99
B02AB01	aprotinin	0,00	100	1 567	40	100	1 926
B02AB02	alfa1 antitrypsin	0,00	100	30	69	100	30
B02B	VITAMIN K AND OTHER HEMOSTATICS	0,08	35	-51	56 600	26	-25
B02BA	Vitamin K	0,02	87	-48	156	87	-48
B02BA01	phytomenadione	0,02	87	-48	156	87	-48
B02BB	Fibrinogen	0,00	100	-22	1 484	100	-22
B02BB01	fibrinogen, human	0,00	100	-22	1 484	100	-22
B02BC	Local hemostatics	-	-	-	3 391	99	-2
B02BC30	combinations	-	-	-	3 391	99	-2
B02BD	Blood coagulation factors	0,03	19	-73	47 523	20	-29

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
B02BD01	coagulation factor IX, II, VII and X in combination	0,00	100	-62	5 738	100	-13
B02BD02	coagulation factor VIII	0,02	4	-72	25 506	4	-25
B02BD03	factor VIII inhibitor bypassing activity	0,00	30	-78	1 307	22	-44
B02BD04	coagulation factor IX	0,01	8	-78	6 533	6	-53
B02BD06	von Willebrand factor and coagulation factor VIII in combination	-	-	-	6 467	18	1
B02BD07	coagulation factor XIII	0,00	33	-79	739	33	-49
B02BD08	coagulation factor VIIa	-	-	-	464	84	-39
B02BD10	von Willebrand factor	0,00	20	-51	769	43	-19
B02BX	Other systemic hemostatics	0,03	8	34	4 046	8	34
B02BX04	romiplostim	0,01	9	29	1 331	9	28
B02BX05	eltrombopag	0,02	8	37	2 700	8	36
B02BX06	emicizumab	0,00	0	-	16	0	-
B03	ANTIANEMIC PREPARATIONS	20,22	6	-13	26 176	26	1
B03A	IRON PREPARATIONS	5,76	4	12	9 268	52	28
B03AA	Iron bivalent, oral preparations	4,21	4	4	3 054	3	10
B03AA01	ferrous glycine sulphate	3,09	4	3	2 454	3	11
B03AA07	ferrous sulphate	1,12	3	6	600	3	6
B03AB	Iron trivalent, oral preparations	1,50	2	42	1 231	3	31
B03AB05	ferric oxide polymaltose complexes	1,50	2	42	1 229	3	31
B03AB10	ferric maltol	-	-	-	2	6	3 353
B03AC	Iron, parenteral preparations	0,05	100	55	4 919	95	42
B03AD	Iron in combination with folic acid	-	-	-	64	2	2
B03AD01	ferrous amino acid complex	-	-	-	64	2	2
B03B	VITAMIN B12 AND FOLIC ACID	13,40	6	-21	1 951	6	-38
B03BA	Vitamin B12 (cyanocobalamin and derivatives)	6,15	7	-37	1 160	6	-51
B03BA01	cyanocobalamin	1,10	4	-76	364	4	-77
B03BA03	hydroxocobalamin	5,05	7	-2	796	7	-2
B03BB	Folic acid, combinations	7,26	6	1	791	6	2
B03BB01	folic acid	7,26	6	1	791	6	2
B03X	OTHER ANTIANEMIC PREPARATIONS	1,06	13	-2	14 957	13	-4
B03XA	Other antianemic preparations	1,06	13	-2	14 957	13	-4
B03XA01	erythropoietin	0,17	18	-35	2 014	18	-38
B03XA02	darbepoetin alfa	0,72	12	10	10 397	12	7

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
B03XA03	methoxy polyethylene glycolepoetin beta	0,17	10	5	2 546	10	0
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS	-	-	-	31 955	77	-1
B05A	BLOOD AND RELATED PRODUCTS	-	-	-	3 638	100	8
B05AA	Blood substitutes and plasma protein fractions	-	-	-	3 638	100	8
B05AA01	albumin	-	-	-	3 606	100	8
B05AA05	dextran	-	-	-	1	100	-88
B05AA06	gelatin agents	-	-	-	15	98	-35
B05AA07	hydroxyethylstarch	-	-	-	15	96	-23
B05B	I.V. SOLUTIONS	-	-	-	19 209	99	-5
B05BA	Solutions for parenteral nutrition	-	-	-	5 213	100	3
B05BA01	amino acids	-	-	-	110	100	-12
B05BA02	fat emulsions	-	-	-	47	97	-6
B05BA03	carbohydrates	-	-	-	460	99	0
B05BA10	combinations	-	-	-	4 595	100	4
B05BB	Solutions affecting the electrolyte balance	-	-	-	13 968	99	-8
B05BB01	electrolytes	-	-	-	12 886	99	-8
B05BB02	electrolytes with carbohydrates	-	-	-	1 082	100	-6
B05BC	Solutions producing osmotic diuresis	-	-	-	28	99	3
B05BC01	mannitol	-	-	-	28	99	3
B05D	PERITONEAL DIALYTICS	-	-	-	7 664	7	4
B05DA	Isotonic solutions	-	-	-	3 934	5	-4
B05DB	Hypertonic solutions	-	-	-	3 730	8	15
B05X	I.V. SOLUTION ADDITIVES	-	-	-	1 277	98	6
B05XA	Electrolyte solutions	-	-	-	842	98	7
B05XA01	potassium chloride	-	-	-	295	100	-3
B05XA03	sodium chloride	-	-	-	181	94	-3
B05XA05	magnesium sulphate	-	-	-	74	100	665
B05XA06	potassium phosphate, incl. comb. with other potassium salts	-	-	-	34	98	-12
B05XA14	sodium glycerophosphate	-	-	-	68	97	16
B05XA31	electrolytes in combination with other drugs	-	-	-	190	98	0
B05XB	Amino acids	-	-	-	41	100	0
B05XB02	alanyl glutamine	-	-	-	41	100	0

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
B05XC	Vitamins	-	-	-	394	99	5
B05Z	HEMODIALYTICS AND HEMOFILTRATES	-	-	-	167	100	58
B05ZB	Hemofiltrates	-	-	-	167	100	58
B06	OTHER HEMATOLOGICAL AGENTS	0,00	21	-12	5 025	19	-16
B06A	OTHER HEMATOLOGICAL AGENTS	0,00	21	-12	5 025	19	-16
B06AC	Drugs used in hereditary angioedema	0,00	21	-12	5 025	19	-16
B06AC01	c1-inhibitor, plasma derived	0,00	17	1	2 745	17	1
B06AC02	icatibant	0,00	13	-35	1 977	13	-35
B06AC04	conestat alfa	0,00	75	148	303	75	24
<b>C</b>	<b>CARDIOVASCULAR SYSTEM</b>	<b>591,51</b>	<b>2</b>	<b>-4</b>	<b>171 984</b>	<b>10</b>	<b>-24</b>
C01	CARDIAC THERAPY	14,80	9	-9	23 072	57	-2
C01A	CARDIAC GLYCOSIDES	2,26	4	-9	1 128	12	-6
C01AA	Digitalis glycosides	2,26	4	-9	1 128	12	-6
C01AA05	digoxin	2,26	4	-9	1 128	12	-6
C01B	ANTIARRHYTHMICS, CLASS I AND III	2,06	4	-33	4 094	34	-36
C01BB	Antiarrhythmics, class IB	0,00	97	-42	181	97	-42
C01BB01	lidocaine	0,00	97	-42	181	97	-42
C01BC	Antiarrhythmics, class IC	1,43	1	-42	1 942	1	-43
C01BC04	flecainide	1,43	1	-42	1 942	1	-43
C01BD	Antiarrhythmics, class III	0,63	12	4	1 209	34	6
C01BD01	amiodarone	0,49	15	6	516	60	29
C01BD05	ibutilide	0,00	99	-18	87	99	-19
C01BD07	dronedarone	0,14	1	-4	607	1	-4
C01BG	Other antiarrhythmics, class I and III	0,00	100	-49	762	100	-49
C01BG11	vernakalant	0,00	100	-49	762	100	-49
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	0,93	86	54	12 247	84	20
C01CA	Adrenergic and dopaminergic agents	0,92	86	54	7 369	73	25
C01CA01	etilefrine	0,06	25	7	392	75	13
C01CA03	norepinephrine	0,06	99	3	1 504	99	19
C01CA04	dopamine	0,00	85	-3	37	86	-7
C01CA06	phenylephrine	0,01	99	195	512	100	16
C01CA07	dobutamine	0,00	99	9	82	99	9
C01CA24	epinephrine	0,79	89	65	4 525	59	33

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C01CA26	ephedrine	-	-	-	318	99	1
C01CE	Phosphodiesterase inhibitors	0,00	100	-	417	100	-
C01CE02	milrinone	0,00	100	-	417	100	-
C01CX	Other cardiac stimulants	0,00	100	3	4 461	100	3
C01CX08	levosimendan	0,00	100	3	4 461	100	3
C01D	VASODILATORS USED IN CARDIAC DISEASES	9,52	4	-5	4 779	12	-5
C01DA	Organic nitrates	9,52	4	-5	4 779	12	-5
C01DA02	glyceryl trinitrate	0,65	10	-10	1 045	33	-6
C01DA08	isosorbide dinitrate	1,63	6	-6	1 082	13	-4
C01DA14	isosorbide mononitrate	7,23	3	-4	2 652	3	-5
C01E	OTHER CARDIAC PREPARATIONS	0,03	61	5	824	94	8
C01EA	Prostaglandins	0,00	98	2	276	98	2
C01EA01	alprostadil	0,00	98	2	276	98	2
C01EB	Other cardiac preparations	0,03	61	5	548	92	11
C01EB10	adenosine	0,02	100	-2	363	98	10
C01EB17	ivabradine	0,01	4	14	38	4	13
C01EB21	regadenoson	0,00	100	13	146	100	15
C02	ANTIHYPERTENSIVES	3,00	3	0	6 979	8	-27
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	2,52	3	-1	1 247	30	0
C02AC	Imidazoline receptor agonists	2,52	3	-1	1 247	30	0
C02AC01	clonidine	0,06	36	5	373	87	18
C02AC02	guanfacine	0,03	18	-6	236	18	-12
C02AC05	moxonidine	2,43	2	-1	638	2	-3
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING	0,43	4	8	342	4	9
C02CA	Alpha-adrenoceptor blocking agents	0,43	4	8	342	4	9
C02CA01	prazosin	0,43	4	8	342	4	9
C02K	OTHER ANTIHYPERTENSIVES	0,05	2	-18	5 391	3	-33
C02KX	Antihypertensives for pulmonary arterial hypertension	0,05	2	-18	5 391	3	-33
C02KX01	bosentan	0,02	2	-5	1 010	3	-47
C02KX02	ambrisentan	0,01	2	-43	816	3	-48
C02KX04	macitentan	0,02	3	-33	2 450	3	-35

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C02KX05	riociguat	0,01	1	33	1 115	1	37
C03	DIURETICS	51,56	6	-11	8 232	18	-6
C03A	LOW-CEILING DIURETICS, THIAZIDES	6,67	2	2	1 223	2	4
C03AA	Thiazides, plain	6,67	2	2	1 223	2	4
C03AA03	hydrochlorothiazide	6,67	2	2	1 223	2	4
C03B	LOW-CEILING DIURETICS, EXCL. THIAZIDES	0,48	1	-4	183	1	-6
C03BA	Sulfonamides, plain	0,48	1	-4	183	1	-6
C03BA11	indapamide	0,48	1	-4	183	1	-6
C03C	HIGH-CEILING DIURETICS	35,11	8	1	4 709	28	6
C03CA	Sulfonamides, plain	35,11	8	1	4 709	28	6
C03CA01	furosemide	35,11	8	1	4 709	28	6
C03D	POTASSIUM-SPARING AGENTS	2,57	3	-2	1 304	3	0
C03DA	Aldosterone antagonists	2,57	3	-2	1 304	3	0
C03DA01	spironolactone	2,55	3	-2	1 233	3	0
C03DA04	eplerenone	0,01	3	3	71	3	4
C03E	DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	6,75	1	-50	770	2	-48
C03EA	Low-ceiling diuretics and potassium-sparing agents	5,89	1	-53	615	1	-53
C03EA01	hydrochlorothiazide and potassium-sparing agents	5,89	1	-53	615	1	-53
C03EB	High-ceiling diuretics and potassium-sparing agents	0,85	5	-12	155	5	-12
C03EB01	furosemide and potassium-sparing agents	0,85	5	-12	155	5	-12
C03X	OTHER DIURETICS	0,00	93	-77	42	93	-77
C03XA	Vasopressin antagonists	0,00	93	-77	42	93	-77
C03XA01	tolvaptan	0,00	93	-77	42	93	-77
C04	PERIPHERAL VASODILATORS	0,11	5	-5	79	5	-5
C04A	PERIPHERAL VASODILATORS	0,11	5	-5	79	5	-5
C04AD	Purine derivatives	0,11	5	-5	79	5	-5
C04AD03	pentoxifylline	0,11	5	-5	79	5	-5
C05	VASOPROTECTIVES	-	-	-	4 584	4	-1
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	-	-	-	2 898	2	-2

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C05AA	Corticosteroids	-	-	-	2 648	2	3
C05AA01	hydrocortisone	-	-	-	58	28	-11
C05AA04	prednisolone	-	-	-	2 190	1	0
C05AA08	fluocortolone	-	-	-	400	2	20
C05AE	Muscle relaxants	-	-	-	125	4	-48
C05AE01	glyceryl trinitrate	-	-	-	125	4	-48
C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use	-	-	-	124	0	2
C05AX03	other preparations, combinations	-	-	-	124	0	2
C05B	ANTIVARICOSE THERAPY	-	-	-	1 686	8	0
C05BA	Heparins or heparinoids for topical use	-	-	-	1 571	2	-1
C05BA01	organo-heparinoid	-	-	-	1 571	2	-1
C05BB	Sclerosing agents for local injection	-	-	-	115	86	17
C05BB02	polidocanol	-	-	-	115	86	17
C07	BETA BLOCKING AGENTS	63,55	2	-2	21 350	5	-10
C07A	BETA BLOCKING AGENTS	58,32	2	0	18 582	5	-9
C07AA	Beta blocking agents, non-selective	2,44	2	-14	1 083	2	-13
C07AA05	propranolol	2,14	2	2	995	2	-3
C07AA07	sotalol	0,30	2	-60	88	2	-60
C07AB	Beta blocking agents, selective	53,59	2	1	16 196	3	-9
C07AB02	metoprolol	10,33	2	-9	5 388	5	-14
C07AB03	atenolol	2,05	2	-2	408	2	-3
C07AB04	acebutolol	0,15	3	-5	80	3	-5
C07AB05	betaxolol	0,68	1	-9	247	1	-9
C07AB07	bisoprolol	38,69	2	4	9 559	2	-6
C07AB09	esmolol	0,00	100	-18	25	100	-9
C07AB12	nebivolol	1,69	1	5	489	1	5
C07AG	Alpha and beta blocking agents	2,28	2	-2	1 303	35	-10
C07AG01	labetalol	0,09	8	-5	601	73	4
C07AG02	carvedilol	2,20	2	-2	702	2	-19
C07B	BETA BLOCKING AGENTS AND THIAZIDES	3,72	0	-19	1 322	0	-23
C07BB	Beta blocking agents, selective, and thiazides	3,72	0	-19	1 322	0	-23
C07BB02	metoprolol and thiazides	0,62	0	-54	290	0	-54
C07BB07	bisoprolol and thiazides	3,10	0	-5	984	0	-5



## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C07BB12	nebivolol and thiazides	-	-	-	48	0	7
C07F	BETA BLOCKING AGENTS, OTHER COMBINATIONS	1,50	0	-6	1 446	0	-6
C07FB	Beta blocking agent and calcium channel blockers	1,50	0	-6	1 446	0	-6
C07FB02	metoprolol and felodipine	1,50	0	-6	1 446	0	-6
C08	CALCIUM CHANNEL BLOCKERS	83,58	1	2	15 798	3	-11
C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	82,04	1	3	14 793	3	-11
C08CA	Dihydropyridine derivatives	82,04	1	3	14 793	3	-11
C08CA01	amlodipine	55,05	1	2	4 288	2	-25
C08CA02	felodipine	7,46	1	4	3 345	1	-3
C08CA03	isradipine	0,22	1	-16	139	1	-26
C08CA05	nifedipine	1,69	2	-27	911	3	-19
C08CA06	nimodipine	0,01	83	-3	274	95	-26
C08CA07	nisoldipine	0,03	3	-67	38	3	-68
C08CA10	nilvadipine	0,77	1	-1	463	1	-1
C08CA13	lercanidipine	16,82	1	9	5 336	1	2
C08D	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	1,54	2	-4	1 004	6	-6
C08DA	Phenylalkylamine derivatives	0,73	2	0	285	16	-4
C08DA01	verapamil	0,73	2	0	285	16	-4
C08DB	Benzothiazepine derivatives	0,81	2	-8	720	2	-7
C08DB01	diltiazem	0,81	2	-8	720	2	-7
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	253,77	1	5	46 539	1	-8
C09A	ACE INHIBITORS, PLAIN	105,10	2	2	9 248	2	-1
C09AA	ACE inhibitors, plain	105,10	2	2	9 248	2	-1
C09AA02	enalapril	22,96	1	1	2 161	2	-3
C09AA03	lisinopril	3,71	1	-2	736	2	-14
C09AA04	perindopril	4,60	1	3	1 734	1	-2
C09AA05	ramipril	73,73	2	2	4 587	2	2
C09AA06	quinapril	0,10	1	-14	30	1	-14
C09B	ACE-INHIBITORS, COMBINATIONS	11,93	0	-2	4 793	0	-10
C09BA	ACE-inhibitors and diuretics	10,11	0	-3	3 510	0	-8

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C09BA02	enalapril and diuretics	6,71	0	-4	2 085	0	-13
C09BA03	lisinopril and diuretics	1,33	0	2	683	0	2
C09BA04	perindopril and diuretics	1,01	1	-2	537	0	-2
C09BA05	ramipril and diuretics	0,98	0	-4	172	0	-4
C09BA06	quinapril and diuretics	0,08	0	-15	33	0	-16
C09BA15	zofenopril and diuretics	-	-	-	0	0	-
C09BB	ACE inhibitors and calcium channel blockers	1,47	0	1	935	0	-22
C09BB02	enalapril and lercanidipine	0,35	0	1	124	0	0
C09BB04	perindopril and amlodipine	1,12	0	11	811	0	-18
C09BB05	ramipril and felodipine	-	-	-100	0	-	-100
C09BX	ACE inhibitors, other combinations	0,35	0	17	348	0	15
C09BX01	perindopril, amlodipine and indapamide	0,33	0	11	334	0	12
C09BX02	perindopril and bisoprolol	0,02	0	480	14	0	461
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN	104,30	1	11	15 536	1	-17
C09CA	Angiotensin II receptor blockers (ARBs), plain	104,30	1	11	15 536	1	-17
C09CA01	losartan	42,54	1	10	7 612	1	-18
C09CA02	eprosartan	0,37	1	-8	321	1	-13
C09CA03	valsartan	15,12	1	15	2 249	2	-17
C09CA06	candesartan	36,84	1	13	4 095	1	-11
C09CA07	telmisartan	8,36	1	5	1 048	2	-22
C09CA08	olmesartan medoxomil	1,07	0	6	210	1	-54
C09D	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS	32,44	0	2	16 961	1	-1
C09DA	Angiotensin II receptor blockers (ARBs) and diuretics	28,15	0	2	9 751	0	-10
C09DA01	losartan and diuretics	12,11	0	4	3 542	0	-7
C09DA02	eprosartan and diuretics	0,38	0	-7	347	0	-7
C09DA03	valsartan and diuretics	4,76	0	7	1 256	0	-16
C09DA06	candesartan and diuretics	6,97	0	1	3 434	0	-3
C09DA07	telmisartan and diuretics	3,59	0	-4	1 013	0	-25
C09DA08	olmesartan medoxomil and diuretics	0,35	0	-2	159	0	-24
C09DB	Angiotensin II receptor blockers (ARBs) and calcium channel blockers	2,59	0	-3	3 295	0	-3

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C09DB01	valsartan and amlodipine	2,47	0	-1	3 173	0	-1
C09DB02	olmesartan medoxomil and amlodipine	0,12	0	-32	122	0	-41
C09DX	Angiotensin II receptor blockers (ARBs), other combinations	1,69	1	10	3 915	2	31
C09DX01	valsartan, amlodipine and hydrochlorothiazide	1,49	0	4	2 181	0	4
C09DX04	valsartan and sacubitril	0,20	4	94	1 735	4	94
C09X	OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	-	-	-100	0	-	-100
C09XA	Renin-inhibitors	-	-	-100	0	-	-100
C09XA02	aliskiren	-	-	-100	0	-	-100
C10	LIPID MODIFYING AGENTS	121,15	1	-19	45 352	1	-49
C10A	LIPID MODIFYING AGENTS, PLAIN	121,05	1	-19	44 980	1	-49
C10AA	HMG CoA reductase inhibitors	115,38	1	-18	38 999	1	-43
C10AA01	simvastatin	37,15	1	-3	17 095	1	-20
C10AA02	lovastatin	0,31	1	-3	240	1	1
C10AA03	pravastatin	2,24	2	-1	1 295	2	-1
C10AA04	fluvastatin	1,90	1	-14	837	1	-23
C10AA05	atorvastatin	49,59	1	-36	11 362	2	-66
C10AA07	rosuvastatin	24,20	1	20	8 171	1	-27
C10AB	Fibrates	0,53	2	-1	447	2	-7
C10AB02	bezafibrate	0,06	1	-1	77	1	-2
C10AB04	gemfibrozil	0,02	1	-13	20	1	-13
C10AB05	fenofibrate	0,44	2	0	350	2	-8
C10AC	Bile acid sequestrants	0,06	2	-43	173	2	-41
C10AC01	colestyramine	0,06	2	-45	159	2	-45
C10AC04	colesevelam	0,00	0	313	14	0	313
C10AX	Other lipid modifying agents	5,08	1	-38	5 360	2	-71
C10AX09	ezetimibe	5,06	1	-38	4 874	2	-73
C10AX13	evolocumab	0,02	5	112	432	5	68
C10AX14	alirocumab	0,00	0	1 071	54	0	715
C10B	LIPID MODIFYING AGENTS, COMBINATIONS	0,10	0	-60	372	0	-48
C10BA	HMG CoA reductase inhibitors in combination with other lipid modifying agents	0,10	0	-60	253	1	-60
C10BA02	simvastatin and ezetimibe	0,10	0	-60	253	1	-60

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
C10BX	HMG CoA reductase inhibitors, other combinations	-	-	-	119	0	55
C10BX11	atorvastatin, amlodipine and perindopril	-	-	-	119	0	55
<b>D</b>	<b>DERMATOLOGICALS</b>	<b>2,85</b>	<b>1</b>	<b>5</b>	<b>41 560</b>	<b>5</b>	<b>2</b>
D01	ANTIFUNGALS FOR DERMATOLOGICAL USE	1,55	1	7	5 816	3	4
D01A	ANTIFUNGALS FOR TOPICAL USE	-	-	-	4 668	4	3
D01AA	Antibiotics	-	-	-	44	4	6
D01AA02	natamycin	-	-	-	44	4	6
D01AC	Imidazole and triazole derivatives	-	-	-	3 023	5	6
D01AC01	clotrimazole	-	-	-	256	1	9
D01AC02	miconazole	-	-	-	978	8	14
D01AC07	tioconazole	-	-	-	29	2	-57
D01AC08	ketoconazole	-	-	-	960	2	3
D01AC20	imidazoles/triazoles in combination with corticosteroids	-	-	-	800	7	6
D01AE	Other antifungals for topical use	-	-	-	1 602	1	-3
D01AE14	ciclopirox	-	-	-	70	0	-4
D01AE15	terbinafine	-	-	-	1 335	2	-4
D01AE16	amorolfine	-	-	-	197	0	3
D01B	ANTIFUNGALS FOR SYSTEMIC USE	1,55	1	7	1 148	1	9
D01BA	Antifungals for systemic use	1,55	1	7	1 148	1	9
D01BA02	terbinafine	1,55	1	7	1 148	1	9
D02	EMOLLIENTS AND PROTECTIVES	-	-	-	2 232	1	9
D02A	EMOLLIENTS AND PROTECTIVES	-	-	-	2 232	1	9
D02AE	Carbamide products	-	-	-	1 198	1	12
D02AE01	carbamide	-	-	-	1 198	1	12
D02AX	Other emollients and protectives	-	-	-	1 034	0	6
D03	PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS	-	-	-	6 548	3	5
D03A	CICATRIZANTS	-	-	-	6 493	3	5
D03AX	Other cicatrizants	-	-	-	6 493	3	5
D03AX03	dexpanthenol	-	-	-	6 493	3	5
D03B	ENZYMES	-	-	-	55	68	-14
D03BA	Proteolytic enzymes	-	-	-	55	68	-14
D03BA02	collagenase	-	-	-	55	68	-14

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	-	-	-	330	0	74
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	-	-	-	330	0	74
D04AA	Antihistamines for topical use	-	-	-	330	0	74
D04AA04	tripelennamine	-	-	-	330	0	74
D05	ANTIPSORIATICS	0,15	2	4	2 172	2	-8
D05A	ANTIPSORIATICS FOR TOPICAL USE	-	-	-	1 777	2	-4
D05AX	Other antipsoriatics for topical use	-	-	-	1 777	2	-4
D05AX02	calcipotriol	-	-	-	38	3	15
D05AX03	calcitriol	-	-	-	42	3	-23
D05AX52	calcipotriol, combinations	-	-	-	1 696	2	-4
D05B	ANTIPSORIATICS FOR SYSTEMIC USE	0,15	2	4	395	2	-24
D05BB	Retinoids for treatment of psoriasis	0,15	2	4	395	2	-24
D05BB02	acitretin	0,15	2	4	395	2	-24
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE	-	-	-	5 077	4	-3
D06A	ANTIBIOTICS FOR TOPICAL USE	-	-	-	2 255	6	20
D06AX	Other antibiotics for topical use	-	-	-	2 255	6	20
D06AX01	fusidic acid	-	-	-	969	11	16
D06AX04	neomycin	-	-	-	1 261	1	24
D06AX09	mupirocin	-	-	-	24	15	13
D06B	CHEMOTHERAPEUTICS FOR TOPICAL USE	-	-	-	2 823	2	-16
D06BA	Sulfonamides	-	-	-	74	55	-17
D06BA01	silver sulfadiazine	-	-	-	74	55	-17
D06BB	Antivirals	-	-	-	2 246	1	-18
D06BB03	aciclovir	-	-	-	1 173	1	-1
D06BB04	podophyllotoxin	-	-	-	66	3	-67
D06BB06	penciclovir	-	-	-	202	0	-5
D06BB10	imiquimod	-	-	-	495	1	16
D06BB53	aciclovir, combinations	-	-	-	310	0	-57
D06BX	Other chemotherapeutics	-	-	-	502	0	-2
D06BX01	metronidazole	-	-	-	349	0	2
D06BX02	ingenol mebutate	-	-	-	153	1	-10

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	-	-	-	11 539	3	2
D07A	CORTICOSTEROIDS, PLAIN	-	-	-	7 904	3	5
D07AA	Corticosteroids, weak (group I)	-	-	-	3 529	2	9
D07AA02	hydrocortisone	-	-	-	3 529	2	9
D07AB	Corticosteroids, moderately potent (group II)	-	-	-	1 359	4	5
D07AB01	clobetasone	-	-	-	8	1	5
D07AB02	hydrocortisone butyrate	-	-	-	714	3	0
D07AB08	desonide	-	-	-	637	5	11
D07AC	Corticosteroids, potent (group III)	-	-	-	2 386	5	0
D07AC01	betamethasone	-	-	-	1 439	7	4
D07AC03	desoximetasone	-	-	-	70	11	28
D07AC13	mometasone	-	-	-	839	2	-9
D07AC14	methylprednisolone aceponate	-	-	-	38	0	-11
D07AD	Corticosteroids, very potent (group IV)	-	-	-	630	4	5
D07AD01	clobetasol	-	-	-	630	4	5
D07B	CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS	-	-	-	1 263	3	-15
D07BA	Corticosteroids, weak, combinations with antiseptics	-	-	-	765	3	7
D07BA04	hydrocortisone and antiseptics	-	-	-	765	3	7
D07BB	Corticosteroids, moderately potent, combinations with antiseptics	-	-	-	307	4	-47
D07BB04	hydrocortisone butyrate and antiseptics	-	-	-	307	4	-47
D07BC	Corticosteroids, potent, combinations with antiseptics	-	-	-	190	5	-3
D07BC01	betamethasone and antiseptics	-	-	-	190	5	-3
D07C	CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS	-	-	-	1 570	4	2
D07CA	Corticosteroids, weak, combinations with antibiotics	-	-	-	921	4	3
D07CA01	hydrocortisone and antibiotics	-	-	-	921	4	3
D07CC	Corticosteroids, potent, combinations with antibiotics	-	-	-	649	4	0

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
D07CC01	betamethasone and antibiotics	-	-	-	649	4	0
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS	-	-	-	802	2	1
D07XA	Corticosteroids, weak, other combinations	-	-	-	294	0	9
D07XA01	hydrocortisone	-	-	-	294	0	9
D07XC	Corticosteroids, potent, other combinations	-	-	-	508	3	-3
D07XC01	betamethasone, combinations	-	-	-	508	3	-3
D08	ANTISEPTICS AND DISINFECTANTS	-	-	-	1 059	63	3
D08A	ANTISEPTICS AND DISINFECTANTS	-	-	-	1 059	63	3
D08AC	Biguanides and amidines	-	-	-	612	92	7
D08AC02	chlorhexidine	-	-	-	229	80	-8
D08AC52	chlorhexidine, combinations	-	-	-	382	100	19
D08AG	Iodine products	-	-	-	448	23	-3
D08AG02	povidone-iodine	-	-	-	448	23	-3
D09	MEDICATED DRESSINGS	-	-	-	139	24	-19
D09A	MEDICATED DRESSINGS	-	-	-	139	24	-19
D09AA	Ointment dressings with antiinfectives	-	-	-	13	33	-7
D09AA02	fusidic acid	-	-	-	13	33	-7
D09AB	Zinc bandages	-	-	-	126	23	-20
D09AB01	zinc bandage without supplements	-	-	-	126	23	-20
D10	ANTI-ACNE PREPARATIONS	1,07	1	2	3 206	1	3
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE	-	-	-	1 806	1	3
D10AD	Retinoids for topical use in acne	-	-	-	483	0	15
D10AD01	tretinoin	-	-	-	175	0	34
D10AD03	adapalene	-	-	-	179	1	-7
D10AD53	adapalene, combinations	-	-	-	130	0	32
D10AE	Peroxides	-	-	-	474	1	-10
D10AE01	benzoyl peroxide	-	-	-	474	1	-10
D10AF	Antiinfectives for treatment of acne	-	-	-	669	1	5
D10AF01	clindamycin	-	-	-	138	2	-32
D10AF51	clindamycin, combinations	-	-	-	532	1	22
D10AX	Other anti-acne preparations for topical use	-	-	-	179	0	2
D10AX03	azelaic acid	-	-	-	179	0	2
D10B	ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE	1,07	1	2	1 400	1	3

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
D10BA	Retinoids for treatment of acne	1,07	1	2	1 400	1	3
D10BA01	isotretinoin	1,07	1	2	1 400	1	3
D11	OTHER DERMATOLOGICAL PREPARATIONS	0,08	1	4	3 441	4	2
D11A	OTHER DERMATOLOGICAL PREPARATIONS	0,08	1	4	3 441	4	2
D11AC	Medicated shampoos	-	-	-	96	0	2
D11AC03	selenium compounds	-	-	-	96	0	2
D11AF	Wart and anti-corn preparations	-	-	-	0	-	-100
D11AH	Agents for dermatitis, excluding corticosteroids	0,02	3	15	2 037	6	2
D11AH01	tacrolimus	-	-	-	1 239	3	-8
D11AH02	pimecrolimus	-	-	-	365	1	-1
D11AH04	alitretinoin	0,02	1	9	321	1	16
D11AH05	dupilumab	0,00	53	-	112	71	-
D11AX	Other dermatologicals	0,07	0	1	1 308	0	4
D11AX01	minoxidil	-	-	-	725	0	8
D11AX10	finasteride	0,07	0	1	223	0	1
D11AX16	eflornithine	-	-	-	33	0	-20
D11AX18	diclofenac	-	-	-	5	5	-7
D11AX21	brimonidine	-	-	-	106	0	-11
D11AX22	ivermectin	-	-	-	208	0	11
D11AX24	deoxycholic acid	-	-	-	8	20	-33
<b>G</b>	<b>GENITO URINARY SYSTEM AND SEX HORMONES</b>	<b>136,70</b>	<b>7</b>	<b>-10</b>	<b>110 117</b>	<b>6</b>	<b>-15</b>
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS	0,67	1	-5	2 660	1	-1
G01A	ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS	0,67	1	-5	2 660	1	-1
G01AA	Antibiotics	0,06	1	-7	395	1	17
G01AA10	clindamycin	0,06	1	-7	395	1	17
G01AC	Quinoline derivatives	0,01	0	149	153	0	149
G01AC05	dequalinium	0,01	0	149	153	0	149
G01AF	Imidazole derivatives	0,59	1	-5	2 112	1	-7
G01AF01	metronidazole	0,17	1	-9	855	1	-12
G01AF02	clotrimazole	0,28	1	-11	1 063	1	-7
G01AF04	miconazole	0,15	2	11	193	2	16



## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
G02	OTHER GYNECOLOGICALS	2,96	10	-51	7 908	34	-47
G02A	UTEROTONICS	0,00	40	-66	87	99	131
G02AB	Ergot alkaloids	0,00	27	-72	1	27	-72
G02AB01	methylergometrine	0,00	27	-72	1	27	-72
G02AD	Prostaglandins	0,00	100	164	86	100	153
G02AD06	misoprostol	0,00	100	164	86	100	153
G02B	CONTRACEPTIVES FOR TOPICAL USE	2,93	10	-51	7 396	30	-48
G02BA	Intrauterine contraceptives	-	-	-	5 540	39	-45
G02BA03	plastic IUD with progestogens	-	-	-	5 540	39	-45
G02BB	Intravaginal contraceptives	2,93	10	-51	1 856	5	-55
G02BB01	vaginal ring with progestogen and estrogen	2,93	10	-51	1 856	5	-55
G02C	OTHER GYNECOLOGICALS	0,03	10	2	425	84	-31
G02CB	Prolactine inhibitors	0,03	9	4	75	11	4
G02CB01	bromocriptine	0,03	9	2	24	9	2
G02CB03	cabergoline	0,01	13	3	45	13	3
G02CB04	quinagolide	0,00	0	15	6	0	16
G02CX	Other gynecologicals	0,00	100	-48	350	100	-35
G02CX01	atosiban	0,00	100	-48	350	100	-35
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	82,78	10	-14	57 820	5	-12
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	46,09	17	-15	18 928	13	-16
G03AA	Progestogens and estrogens, fixed combinations	28,53	15	-23	11 417	12	-23
G03AA07	levonorgestrel and ethinylestradiol	0,59	5	5	160	3	7
G03AA09	desogestrel and ethinylestradiol	3,45	9	-3	985	8	-6
G03AA10	gestodene and ethinylestradiol	5,37	10	-7	1 432	3	-13
G03AA11	norgestimate and ethinylestradiol	0,04	1	-52	13	1	-50
G03AA12	drospirenone and ethinylestradiol	14,88	18	-36	6 567	15	-33
G03AA13	norelgestromin and ethinylestradiol	0,48	5	-2	289	5	-2
G03AA14	nomegestrol and estradiol	3,13	12	1	1 847	12	2
G03AA16	dienogest and ethinylestradiol	0,58	45	3 708	125	24	3 436
G03AB	Progestogens and estrogens, sequential preparations	1,50	6	-6	918	6	-6
G03AB03	levonorgestrel and ethinylestradiol	0,09	0	-17	40	0	-17

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
G03AB05	desogestrel and ethinylestradiol	0,01	0	-42	6	0	-42
G03AB06	gestodene and ethinylestradiol	0,04	0	-22	20	0	-22
G03AB08	dienogest and estradiol	1,36	6	-4	851	6	-4
G03AC	Progestogens	16,00	21	3	5 495	20	-3
G03AC01	norethisterone	0,85	2	7	240	2	5
G03AC03	levonorgestrel	0,45	11	10	272	23	6
G03AC08	etonogestrel	3,99	48	21	925	49	17
G03AC09	desogestrel	10,71	13	-4	4 059	14	-8
G03AD	Emergency contraceptives	0,05	2	6	1 098	2	7
G03AD01	levonorgestrel	0,03	2	1	554	2	-2
G03AD02	ulipristal	0,02	1	18	544	1	18
G03B	ANDROGENS	2,00	0	-4	4 943	0	-5
G03BA	3-oxoandrosten (4) derivatives	2,00	0	-4	4 943	0	-5
G03BA03	testosterone	2,00	0	-4	4 943	0	-5
G03C	ESTROGENS	18,96	1	-20	22 320	1	-4
G03CA	Natural and semisynthetic estrogens, plain	18,25	1	-20	21 998	1	-4
G03CA03	estradiol	12,74	0	-25	20 137	1	-5
G03CA04	estriol	5,52	1	-5	1 861	1	8
G03CX	Other estrogens	0,71	0	-5	322	0	-21
G03CX01	tibolone	0,71	0	-5	322	0	-21
G03D	PROGESTOGENS	2,32	1	8	1 473	0	9
G03DA	Pregnen (4) derivatives	0,43	1	8	533	0	2
G03DA02	medroxyprogesterone	0,21	1	14	40	1	14
G03DA04	progesterone	0,22	0	2	493	0	1
G03DB	Pregnadien derivatives	0,47	0	15	428	0	15
G03DB01	dydrogesterone	0,38	0	15	206	0	15
G03DB08	dienogest	0,09	0	16	222	0	16
G03DC	Estren derivatives	1,42	1	5	512	1	12
G03DC02	norethisterone	1,18	0	5	456	0	12
G03DC03	lynestrenol	0,24	2	8	57	2	8
G03F	PROGESTOGENS AND ESTROGENS IN COMBINATION	9,72	0	-1	4 154	0	0
G03FA	Progestogens and estrogens, combinations	7,60	0	0	3 351	0	0
G03FA01	norethisterone and estrogen	2,94	0	1	1 268	0	3

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
G03FA12	medroxyprogesterone and estrogen	1,23	0	-19	548	0	-19
G03FA14	dydrogesterone and estrogen	2,96	0	9	1 188	0	9
G03FA17	drospirenone and estrogen	0,47	0	-3	347	0	-3
G03FB	Progestogens and estrogens, sequential preparations	2,12	0	-2	803	0	1
G03FB05	norethisterone and estrogen	0,70	0	-2	291	0	4
G03FB06	medroxyprogesterone and estrogen	0,15	0	-13	33	0	-13
G03FB08	dydrogesterone and estrogen	1,27	0	-1	478	0	-1
G03FB09	levonorgestrel and estrogen	-	-	-100	0	-	-100
G03G	GONADOTROPHINS AND OTHER OVULATION STIMULANTS	0,22	0	-39	4 401	0	-35
G03GA	Gonadotrophins	0,22	0	-25	4 401	0	-34
G03GA01	chorionic gonadotrophin	0,13	0	-16	143	0	-10
G03GA02	human menopausal gonadotrophin	0,03	0	-14	1 138	0	-15
G03GA04	urofollitropin	0,00	0	603	56	0	603
G03GA05	follitropin alfa	0,05	0	-39	1 769	0	-44
G03GA06	follitropin beta	0,01	0	-73	216	0	-74
G03GA07	lutropin alfa	0,00	8	-61	1	8	-61
G03GA08	choriogonadotropin alfa	0,00	0	-34	178	0	-32
G03GA09	corifollitropin alfa	0,00	0	-44	290	0	-46
G03GA30	combinations	-	-	-	610	0	63
G03GB	Ovulation stimulants, synthetic	-	-	-100	0	-	-100
G03GB02	clomifene	-	-	-100	0	-	-100
G03H	ANTIANDROGENS	3,46	3	-7	1 276	1	-8
G03HA	Antiandrogens, plain preparations	0,05	6	-2	135	7	-5
G03HA01	cyproterone	0,05	6	-2	135	7	-5
G03HB	Antiandrogens and estrogens	3,40	3	-7	1 141	1	-9
G03HB01	cyproterone and estrogen	3,40	3	-7	1 141	1	-9
G03X	OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	0,03	22	-79	325	45	-73
G03XB	Progesterone receptor modulators	0,03	22	-79	325	45	-73
G03XB01	mifepristone	0,01	98	-45	152	96	-42
G03XB02	ulipristal	0,02	0	-82	173	0	-82
G04	UROLOGICALS	50,29	2	2	41 728	2	-9

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
G04B	UROLOGICALS	18,22	1	-1	20 914	2	-18
G04BD	Drugs for urinary frequency and incontinence	6,80	2	-5	12 348	2	-3
G04BD04	oxybutynin	0,16	2	-17	217	2	-24
G04BD07	tolterodine	0,28	3	-15	378	4	-17
G04BD08	solifenacin	1,51	2	-10	2 340	2	-11
G04BD09	tropium	0,21	1	-11	229	1	-11
G04BD10	darifenacin	0,06	3	-12	84	4	-11
G04BD11	fesoterodine	0,55	2	-55	841	2	-56
G04BD12	mirabegron	4,02	2	17	8 259	2	17
G04BE	Drugs used in erectile dysfunction	8,11	0	4	7 451	1	-37
G04BE01	alprostadil	0,06	0	-2	825	1	-3
G04BE03	sildenafil	7,38	0	4	1 743	3	-56
G04BE08	tadalafil	0,65	0	7	4 621	0	-31
G04BE09	varденаfil	0,01	0	-25	128	0	-31
G04BE10	avanafil	0,01	0	-29	71	0	-29
G04BE30	combinations	0,00	2	-	62	2	176
G04BX	Other urologicals	3,32	3	-5	1 115	2	-5
G04BX01	magnesium hydroxide	3,31	3	-5	1 071	2	-5
G04BX14	dapoxetine	0,01	0	-1	45	0	-2
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	32,07	2	4	20 814	2	2
G04CA	Alpha-adrenoreceptor antagonists	22,78	2	5	14 689	1	6
G04CA01	alfuzosin	5,60	1	4	2 527	1	6
G04CA02	tamsulosin	11,27	2	3	3 449	2	1
G04CA52	tamsulosin and dutasteride	5,89	1	10	8 631	1	9
G04CA53	tamsulosin and solifenacin	0,02	1	-	82	1	-4
G04CB	Testosterone-5-alpha reductase inhibitors	8,44	2	1	5 508	2	-9
G04CB01	finasteride	6,39	2	-2	4 805	2	2
G04CB02	dutasteride	2,05	3	8	702	3	-46
G04CX	Other drugs used in benign prostatic hypertrophy	0,85	0	15	618	0	13
G04CX02	sabalıs serrulatae fructus	0,85	0	15	618	0	13
<b>H</b>	<b>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</b>	<b>55,91</b>	<b>6</b>	<b>4</b>	<b>47 033</b>	<b>20</b>	<b>3</b>
H01	PITUITARY, HYPOTHALAMIC HORMONES AND ANALOGUES	1,07	4	23	26 788	10	4

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
H01A	ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES	0,17	1	2	8 914	14	0
H01AB	Thyrotrophin	0,00	100	5	1 238	100	5
H01AB01	thyrotrophin alfa	0,00	100	5	1 238	100	5
H01AC	Somatropin and somatropin agonists	0,17	0	4	7 235	0	4
H01AC01	somatropin	0,17	0	4	7 235	0	4
H01AX	Other anterior pituitary hormones and analogues	0,00	1	-40	441	1	-40
H01AX01	pegvisomant	0,00	1	-40	441	1	-40
H01B	POSTERIOR PITUITARY LOBE HORMONES	0,62	5	39	2 440	25	0
H01BA	Vasopressin and analogues	0,60	2	42	2 250	19	3
H01BA02	desmopressin	0,60	2	42	1 932	5	2
H01BA04	terlipressin	0,00	100	-3	318	100	13
H01BB	Oxytocin and analogues	0,02	100	-20	190	100	-30
H01BB02	oxytocin	0,02	100	-21	177	100	-33
H01BB03	carbetocin	0,00	100	115	13	100	209
H01C	HYPOTHALAMIC HORMONES	0,27	3	9	15 434	4	7
H01CA	Gonadotrophin-releasing hormones	0,04	0	21	232	0	21
H01CA02	nafarelin	0,04	0	21	232	0	21
H01CB	Somatostatin and analogues	0,22	3	13	14 763	5	13
H01CB02	octreotide	0,12	6	7	7 797	8	7
H01CB03	lanreotide	0,10	1	20	6 921	1	20
H01CB05	pasireotide	0,00	0	64	45	0	64
H01CC	Anti gonadotropin releasing hormones	0,01	0	-48	439	0	-62
H01CC01	ganirelix	0,01	0	-42	376	0	-59
H01CC02	cetrorelix	0,00	0	-71	62	0	-72
H02	CORTICOSTEROIDS FOR SYSTEMIC USE	18,92	16	3	10 538	57	0
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	18,82	15	3	8 303	54	4
H02AA	Mineralocorticoids	0,69	7	3	154	7	3
H02AA02	fludrocortisone	0,69	7	3	154	7	3
H02AB	Glucocorticoids	18,14	16	3	8 149	55	4
H02AB01	betamethasone	0,17	95	-18	216	87	-2
H02AB02	dexamethasone	2,18	40	1	1 544	78	2
H02AB04	methylprednisolone	1,16	40	2	1 941	74	-6

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
H02AB06	prednisolone	12,25	8	3	1 540	20	10
H02AB07	prednisone	0,86	8	-11	132	7	-12
H02AB08	triamcinolone	0,09	76	-2	878	75	-2
H02AB09	hydrocortisone	1,41	15	16	1 898	35	20
H02B	CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS	0,09	69	-12	2 235	69	-12
H02BX	Corticosteroids for systemic use, combinations	0,09	69	-12	2 235	69	-12
H02BX01	methylprednisolone, combinations	0,09	69	-12	2 235	69	-12
H03	THYROID THERAPY	35,68	1	5	6 875	2	5
H03A	THYROID PREPARATIONS	35,10	1	5	6 166	1	5
H03AA	Thyroid hormones	35,10	1	5	6 166	1	5
H03AA01	levothyroxine sodium	35,10	1	5	6 166	1	5
H03B	ANTITHYROID PREPARATIONS	0,59	5	0	709	5	0
H03BB	Sulphur-containing imidazole derivatives	0,59	5	0	709	5	0
H03BB01	carbimazole	0,59	5	0	709	5	0
H04	PANCREATIC HORMONES	0,01	69	7	251	65	6
H04A	GLYCOGENOLYTIC HORMONES	0,01	69	7	251	65	6
H04AA	Glycogenolytic hormones	0,01	69	7	251	65	6
H04AA01	glucagon	0,01	69	7	251	65	6
H05	CALCIUM HOMEOSTASIS	0,23	11	7	2 580	13	0
H05A	PARATHYROID HORMONES AND ANALOGUES	0,06	5	1	1 343	5	1
H05AA	Parathyroid hormones and analogues	0,06	5	1	1 343	5	1
H05AA02	teriparatide	0,06	5	1	1 343	5	1
H05B	ANTI-PARATHYROID AGENTS	0,17	13	9	1 237	22	-1
H05BA	Calcitonin preparations	0,00	98	53	99	98	641
H05BA01	calcitonin (salmon synthetic)	0,00	98	53	99	98	641
H05BX	Other anti-parathyroid agents	0,17	12	9	1 137	16	-8
H05BX01	cinacalcet	0,15	7	15	983	10	-7
H05BX02	paricalcitol	0,02	45	-21	144	49	-19
H05BX04	etelcalcetide	0,00	100	60	10	100	60
<b>J</b>	<b>ANTIINFECTIVES FOR SYSTEMIC USE</b>	<b>19,13</b>	<b>19</b>	<b>-6</b>	<b>246 844</b>	<b>74</b>	<b>0</b>
J01	ANTIBACTERIALS FOR SYSTEMIC USE	16,90	14	-5	49 940	50	-12
J01A	TETRACYCLINES	3,20	5	-7	2 404	32	-7
J01AA	Tetracyclines	3,20	5	-7	2 404	32	-7

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J01AA02	doxycycline	2,03	7	-6	1 203	18	-3
J01AA04	lymecycline	0,77	1	-5	463	1	-5
J01AA07	tetracycline	0,40	2	-12	189	2	-12
J01AA12	tigecycline	0,00	98	-19	550	98	-15
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS	6,37	11	-6	17 162	45	-11
J01CA	Penicillins with extended spectrum	3,61	8	-3	7 216	19	0
J01CA01	ampicillin	0,02	100	-17	959	100	4
J01CA04	amoxicillin	2,93	7	-3	4 689	6	-1
J01CA08	pivmecillinam	0,66	9	-3	1 567	7	-2
J01CE	Beta-lactamase sensitive penicillins	1,29	8	4	2 133	55	32
J01CE01	benzylpenicillin	0,06	99	48	1 152	100	62
J01CE02	phenoxymethylpenicillin	1,23	4	2	981	3	8
J01CF	Beta-lactamase resistant penicillins	0,17	56	11	881	63	18
J01CF02	cloxacillin	0,09	97	0	534	97	12
J01CF05	flucloxacillin	0,08	10	27	347	10	29
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors	1,30	14	-22	6 932	66	-28
J01CR02	amoxicillin and beta-lactamase inhibitor	1,23	9	-22	2 486	7	-17
J01CR05	piperacillin and beta-lactamase inhibitor	0,07	100	-19	4 446	100	-32
J01D	OTHER BETA-LACTAM ANTIBACTERIALS	2,92	34	4	14 827	62	-15
J01DB	First-generation cephalosporins	2,00	6	-1	5 774	5	0
J01DB01	cefalexin	2,00	6	-1	5 771	5	0
J01DB04	cefazolin	0,00	100	1 286	3	100	1 382
J01DC	Second-generation cephalosporins	0,77	96	29	4 629	98	-3
J01DC02	cefuroxime	0,77	96	29	4 627	98	-3
J01DC04	cefaclor	0,00	0	-82	2	0	-82
J01DD	Third-generation cephalosporins	0,07	97	-22	1 321	93	-8
J01DD01	cefotaxime	0,00	99	92	3	93	-61
J01DD02	ceftazidime	0,01	100	5	187	100	-34
J01DD04	ceftriaxone	0,07	96	-24	1 010	93	-9
J01DD52	ceftazidime and beta-lactamase inhibitor	0,00	91	320	121	91	320
J01DE	Fourth-generation cephalosporins	0,00	100	450	4	100	148
J01DE01	cefepime	0,00	100	450	4	100	148
J01DF	Monobactams	0,00	100	-6	43	100	-6

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J01DF01	aztreonam	0,00	100	-6	43	100	-6
J01DH	Carbapenems	0,07	99	-26	2 750	99	-45
J01DH02	meropenem	0,06	99	-7	1 640	99	-17
J01DH03	ertapenem	0,01	100	-63	1 111	100	-63
J01DI	Other cephalosporins and penems	0,00	100	-23	306	100	-35
J01DI02	ceftaroline fosamil	0,00	100	103	77	100	103
J01DI54	ceftolozane and beta-lactamase inhibitor	0,00	100	-47	229	100	-47
J01E	SULFONAMIDES AND TRIMETHOPRIM	1,09	8	-10	1 477	10	-6
J01EA	Trimethoprim and derivatives	0,74	6	-4	818	6	-2
J01EA01	trimethoprim	0,74	6	-4	818	6	-2
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives	0,35	12	-20	659	14	-11
J01EE01	sulfamethoxazole and trimethoprim	0,14	16	-35	162	40	-23
J01EE02	sulfadiazine and trimethoprim	0,21	9	-6	498	6	-6
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS	0,83	16	-7	3 764	35	-20
J01FA	Macrolides	0,55	12	-8	1 662	23	-17
J01FA01	erythromycin	0,00	99	26	79	99	23
J01FA06	roxithromycin	0,10	9	-3	153	8	-17
J01FA09	clarithromycin	0,12	15	-17	449	19	-16
J01FA10	azithromycin	0,33	12	-3	982	21	-17
J01FA15	telithromycin	-	-	-100	0	-	-100
J01FF	Lincosamides	0,28	23	-5	2 102	44	-23
J01FF01	clindamycin	0,28	23	-5	2 102	44	-23
J01G	AMINOGLYCOSIDE ANTIBACTERIALS	0,02	49	15	1 194	51	19
J01GB	Other aminoglycosides	0,02	49	15	1 194	51	19
J01GB01	tobramycin	0,01	40	18	794	27	20
J01GB03	gentamicin	0,00	95	0	211	98	22
J01GB06	amikacin	0,00	100	15	190	100	16
J01M	QUINOLONE ANTIBACTERIALS	0,82	25	-8	3 462	43	-14
J01MA	Fluoroquinolones	0,82	25	-8	3 462	43	-14
J01MA01	ofloxacin	-	-	-100	0	-	-100
J01MA02	ciprofloxacin	0,48	17	-7	1 750	28	-12
J01MA12	levofloxacin	0,25	36	-7	1 175	52	-9



## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J01MA14	moxifloxacin	0,09	37	-13	538	70	-27
J01X	OTHER ANTIBACTERIALS	1,65	10	-2	5 650	66	-8
J01XA	Glycopeptide antibacterials	0,03	100	12	1 497	100	26
J01XA01	vancomycin	0,03	100	11	1 175	100	22
J01XA02	teicoplanin	0,00	100	23	279	100	23
J01XA04	dalbavancin	0,00	100	-	43	100	-
J01XB	Polymyxins	0,00	0	146	119	0	144
J01XB01	colistin	0,00	0	146	119	0	144
J01XC	Steroid antibacterials	0,00	13	-23	12	12	-21
J01XC01	fusidic acid	0,00	13	-23	12	12	-21
J01XD	Imidazole derivatives	0,06	100	19	982	100	-25
J01XD01	metronidazole	0,06	100	19	982	100	-25
J01XE	Nitrofurane derivatives	0,35	4	-24	605	3	-15
J01XE01	nitrofurantoin	0,35	4	-24	605	3	-15
J01XX	Other antibacterials	1,21	5	5	2 434	51	-16
J01XX01	fosfomicin	0,00	100	-	10	100	-
J01XX05	methenamine	1,19	4	5	1 030	5	4
J01XX08	linezolid	0,01	68	7	824	74	-17
J01XX09	daptomycin	0,00	100	-38	568	100	-38
J01XX11	tedizolid	0,00	0	-	2	0	-
J02	ANTIMYCOTICS FOR SYSTEMIC USE	0,40	16	-6	16 810	76	-28
J02A	ANTIMYCOTICS FOR SYSTEMIC USE	0,40	16	-6	16 810	76	-28
J02AA	Antibiotics	0,01	100	-2	2 359	100	-3
J02AA01	amphotericin	0,01	100	-2	2 359	100	-3
J02AB	Imidazole derivatives	0,00	100	-67	1	100	-67
J02AB02	ketoconazole	0,00	100	-67	1	100	-67
J02AC	Triazole derivatives	0,38	12	-5	5 245	23	-25
J02AC01	fluconazole	0,27	15	-4	2 844	12	-13
J02AC02	itraconazole	0,10	2	0	392	3	-4
J02AC03	voriconazole	0,01	24	-34	796	46	-50
J02AC04	posaconazole	0,00	48	-46	873	48	-46
J02AC05	isavuconazole	0,00	19	258	341	27	246
J02AX	Other antimycotics for systemic use	0,01	100	-35	9 205	100	-34
J02AX04	caspofungin	0,00	100	-53	3 458	100	-54

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J02AX05	micafungin	0,00	100	34	3 934	100	33
J02AX06	anidulafungin	0,00	100	-48	1 814	100	-48
J04	ANTIMYCOBACTERIALS	0,18	86	-4	1 071	90	18
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS	0,18	86	-4	1 071	90	18
J04AA	Aminosalicic acid and derivatives	0,00	100	-43	24	100	-43
J04AA01	aminosalicylic acid	0,00	100	-43	24	100	-43
J04AB	Antibiotics	0,09	74	20	444	76	17
J04AB02	rifampicin	0,09	73	22	377	73	22
J04AB04	rifabutin	0,01	90	-6	68	90	-7
J04AC	Hydrazides	0,04	98	-30	84	98	-26
J04AC01	isoniazid	0,04	98	-30	84	98	-26
J04AK	Other drugs for treatment of tuberculosis	0,04	100	-10	518	100	41
J04AK01	pyrazinamide	0,02	100	-12	72	100	-10
J04AK02	ethambutol	0,03	100	-12	191	100	-12
J04AK05	bedaquiline	0,00	100	267	255	100	267
J05	ANTIVIRALS FOR SYSTEMIC USE	1,65	59	-15	113 142	93	25
J05A	DIRECT ACTING ANTIVIRALS	1,65	59	-15	113 142	93	25
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors	0,63	8	8	10 645	38	6
J05AB01	aciclovir	0,27	4	5	2 703	24	-6
J05AB06	ganciclovir	0,00	100	-27	168	100	-41
J05AB09	famciclovir	0,01	3	31	137	5	33
J05AB11	valaciclovir	0,32	3	9	4 543	3	10
J05AB14	valganciclovir	0,03	100	35	3 094	100	20
J05AE	Protease inhibitors	0,06	100	-27	2 652	100	-30
J05AE01	saquinavir	0,00	100	-48	12	100	-49
J05AE03	ritonavir	0,01	100	-55	198	100	-60
J05AE07	fosamprenavir	0,00	100	-86	6	100	-86
J05AE08	atazanavir	0,02	100	-23	669	100	-34
J05AE10	darunavir	0,03	100	-17	1 767	100	-20
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors	0,07	99	-28	1 181	99	-45
J05AF01	zidovudine	0,00	100	0	14	100	0
J05AF05	lamivudine	0,01	98	-58	77	98	-58

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J05AF06	abacavir	0,00	100	-65	81	100	-65
J05AF07	tenofovir disoproxil	0,04	100	-15	639	100	-51
J05AF08	adefovir dipivoxil	0,00	100	-52	32	100	-52
J05AF09	emtricitabine	0,00	100	-58	9	100	-58
J05AF10	entecavir	0,00	95	17	118	96	8
J05AF13	tenofovir alafenamide	0,01	100	-6	211	100	-6
J05AG	Non-nucleoside reverse transcriptase inhibitors	0,05	100	-1	963	100	-8
J05AG01	nevirapine	0,02	100	-8	496	100	-8
J05AG03	efavirenz	0,01	100	14	115	100	-15
J05AG04	etravirine	0,01	100	-20	202	100	-20
J05AG05	rilpivirine	0,01	100	28	151	100	28
J05AH	Neuraminidase inhibitors	0,14	32	20	1 409	32	15
J05AH01	zanamivir	-	-	-100	0	-	-100
J05AH02	oseltamivir	0,14	32	20	1 409	32	15
J05AP	Antivirals for treatment of HCV infections	0,07	100	34	64 610	100	191
J05AP01	ribavirin	0,01	100	-64	545	100	-64
J05AP05	simeprevir	-	-	-100	0	-	-100
J05AP08	sofosbuvir	0,00	100	-95	42	100	-95
J05AP09	dasabuvir	0,00	100	-98	1	100	-98
J05AP51	sofosbuvir and ledipasvir	0,00	100	-79	312	100	-79
J05AP53	ombitasvir, paritaprevir and ritonavir	0,00	100	-98	14	100	-98
J05AP54	elbasvir and grazoprevir	0,02	100	182	22 937	100	183
J05AP55	sofosbuvir and velpatasvir	0,03	100	416	40 246	100	416
J05AP56	sofosbuvir, velpatasvir and voxilaprevir	0,00	100	-	108	100	-
J05AP57	glecaprevir and pibrentasvir	0,00	100	-76	406	100	-76
J05AR	Antivirals for treatment of HIV infections, combinations	0,45	100	-36	24 398	100	-38
J05AR01	zidovudine and lamivudine	0,00	96	-44	23	97	-59
J05AR02	lamivudine and abacavir	0,04	100	-41	792	100	-68
J05AR03	tenofovir disoproxil and emtricitabine	0,06	100	68	2 757	100	74
J05AR04	zidovudine, lamivudine and abacavir	0,00	100	-58	11	100	-58
J05AR06	emtricitabine, tenofovir disoproxil and efavirenz	0,02	100	-49	1 249	100	-50
J05AR08	emtricitabine, tenofovir disoproxil and rilpivirine	0,00	97	-56	203	97	-55
J05AR09	emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat	0,00	100	-66	205	100	-69

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J05AR10	lopinavir and ritonavir	0,00	100	-57	138	100	-62
J05AR13	lamivudine, abacavir and dolutegravir	0,09	100	-46	6 992	100	-47
J05AR14	darunavir and cobicistat	0,00	100	48	177	100	48
J05AR17	emtricitabine and tenofovir alafenamide	0,13	100	-46	5 171	100	-48
J05AR18	emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat	0,04	100	-31	3 136	100	-37
J05AR19	emtricitabine, tenofovir alafenamide and rilpivirine	0,03	100	-26	2 050	100	-29
J05AR20	emtricitabine, tenofovir alafenamide and bictegravir	-	-	-	942	100	-
J05AR21	dolutegravir and rilpivirine	-	-	-	59	100	-
J05AR22	emtricitabine, tenofovir alafenamide, darunavir and cobicistat	0,01	100	2 218	495	100	2 218
J05AX	Other antivirals	0,19	100	-28	7 285	100	-32
J05AX07	enfuvirtide	0,00	100	-93	2	100	-93
J05AX08	raltegravir	0,07	100	-34	2 195	100	-45
J05AX09	maraviroc	0,00	100	-42	75	100	-45
J05AX12	dolutegravir	0,12	100	-23	5 012	100	-24
J06	IMMUNE SERA AND IMMUNOGLOBULINS	-	-	-	40 633	81	-6
J06B	IMMUNOGLOBULINS	-	-	-	40 633	81	-6
J06BA	Immunoglobulins, normal human	-	-	-	39 068	80	-4
J06BA01	immunoglobulins, normal human, for extravascular adm.	-	-	-	7 852	3	11
J06BA02	immunoglobulins, normal human, for intravascular adm.	-	-	-	31 217	100	-7
J06BB	Specific immunoglobulins	-	-	-	1 565	100	-37
J06BB01	anti-D (rh) immunoglobulin	-	-	-	618	100	-9
J06BB16	palivizumab	-	-	-	793	100	-43
J06BB21	bezlotoxumab	-	-	-	153	100	-63
J07	VACCINES	-	-	-	25 248	18	-22
J07A	BACTERIAL VACCINES	-	-	-	6 403	46	-50
J07AE	Cholera vaccines	-	-	-	140	12	9
J07AE01	cholera, inactivated, whole cell	-	-	-	140	12	9
J07AG	Haemophilus influenzae B vaccines	-	-	-	3	94	-
J07AG01	haemophilus influenzae B, purified antigen conjugated	-	-	-	3	94	-

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J07AH	Meningococcal vaccines	-	-	-	847	80	-80
J07AH07	meningococcus C, purified polysaccharides antigen conjugated	-	-	-	0	-	-100
J07AH08	meningococcus A, C, Y, W-135, tetravalent purified polysaccharides antigen conjugated	-	-	-	829	81	-80
J07AH09	meningococcus B, multicomponent vaccine	-	-	-	17	20	539
J07AJ	Pertussis vaccines	-	-	-	259	3	-27
J07AJ52	pertussis, purified antigen, combinations with toxoids	-	-	-	259	3	-27
J07AL	Pneumococcal vaccines	-	-	-	4 669	47	-41
J07AL01	pneumococcus, purified polysaccharides antigen	-	-	-	83	18	-27
J07AL02	pneumococcus, purified polysaccharides antigen conjugated	-	-	-	4 586	48	-41
J07AM	Tetanus vaccines	-	-	-	283	1	170
J07AM51	tetanus toxoid, combinations with diphtheria toxoid	-	-	-	283	1	170
J07AP	Typhoid vaccines	-	-	-	202	5	-16
J07AP01	typhoid, oral, live attenuated	-	-	-	143	3	-35
J07AP03	typhoid, purified polysaccharide antigen	-	-	-	59	12	190
J07B	VIRAL VACCINES	-	-	-	18 818	9	-4
J07BA	Encephalitis vaccines	-	-	-	5 792	15	-19
J07BA01	encephalitis, tick borne, inactivated, whole virus	-	-	-	5 226	16	-14
J07BA02	encephalitis, Japanese, inactivated, whole virus	-	-	-	567	1	-47
J07BB	Influenza vaccines	-	-	-	2 685	2	28
J07BB02	influenza, purified antigen	-	-	-	2 587	2	30
J07BB03	influenza, live attenuated	-	-	-	98	0	-16
J07BC	Hepatitis vaccines	-	-	-	9 194	8	1
J07BC01	hepatitis B, purified antigen	-	-	-	1 410	26	1
J07BC02	hepatitis A, inactivated, whole virus	-	-	-	1 309	6	-8
J07BC20	combinations	-	-	-	6 475	4	3
J07BD	Measles vaccines	-	-	-	122	0	99
J07BD52	measles, combinations with mumps and rubella, live attenuated	-	-	-	122	0	99
J07BF	Poliomyelitis vaccines	-	-	-	26	31	-43
J07BF03	poliomyelitis, trivalent, inactivated, whole virus	-	-	-	26	31	-43

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
J07BH	Rota virus diarrhea vaccines	-	-	-	3	0	-40
J07BH02	rota virus, pentavalent, live, reassorted	-	-	-	3	0	-40
J07BK	Varicella zoster vaccines	-	-	-	420	3	-24
J07BK01	varicella, live attenuated	-	-	-	288	5	-35
J07BK02	zoster, live attenuated	-	-	-	132	1	17
J07BL	Yellow fever vaccines	-	-	-	383	4	0
J07BL01	yellow fever, live attenuated	-	-	-	383	4	0
J07BM	Papillomavirus vaccines	-	-	-	192	6	95
J07BM01	papillomavirus (human types 6, 11, 16, 18)	-	-	-	0	-	-100
J07BM03	ppapillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)	-	-	-	192	6	335
J07C	BACTERIAL AND VIRAL VACCINES, COMBINED	-	-	-	27	1	196
J07CA	Bacterial and viral vaccines, combined	-	-	-	27	1	196
J07CA02	diphtheria, pertussis, poliomyelitis, tetanus	-	-	-	13	1	155
J07CA06	diphtheria, Haemophilus influenzae B, pertussis, poliomyelitis, tetanus	-	-	-	5	0	23
J07CA10	typhoid - hepatitis A	-	-	-	9	0	-
<b>L</b>	<b>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>	<b>22,15</b>	<b>10</b>	<b>-5</b>	<b>686 484</b>	<b>44</b>	<b>-10</b>
L01	ANTINEOPLASTIC AGENTS	-	-	-	261 196	75	1
L01A	ALKYLATING AGENTS	-	-	-	4 937	65	-12
L01AA	Nitrogen mustard analogues	-	-	-	2 544	94	-22
L01AA01	cyclophosphamide	-	-	-	816	96	-9
L01AA02	chlorambucil	-	-	-	113	16	40
L01AA03	melphalan	-	-	-	63	39	-13
L01AA06	ifosfamide	-	-	-	407	100	2
L01AA09	bendamustine	-	-	-	1 143	100	-37
L01AB	Alkyl sulphonates	-	-	-	119	100	-11
L01AB01	busulfan	-	-	-	119	100	-11
L01AC	Ethylene imines	-	-	-	421	100	35
L01AC01	thiotepa	-	-	-	421	100	35
L01AD	Nitrosoureas	-	-	-	42	99	44
L01AD01	carmustine	-	-	-	13	100	-
L01AD02	lomustine	-	-	-	29	99	0

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01AX	Other alkylating agents	-	-	-	1 812	13	-2
L01AX03	temozolomide	-	-	-	1 693	7	0
L01AX04	dacarbazine	-	-	-	118	100	-26
L01B	ANTIMETABOLITES	-	-	-	18 147	83	-17
L01BA	Folic acid analogues	-	-	-	6 942	98	0
L01BA01	methotrexate	-	-	-	636	73	-26
L01BA04	pemetrexed	-	-	-	6 306	100	4
L01BB	Purine analogues	-	-	-	1 395	27	170
L01BB02	mercaptopurine	-	-	-	97	18	76
L01BB04	cladribine	-	-	-	1 014	14	722
L01BB05	fludarabine	-	-	-	176	60	-6
L01BB06	clofarabine	-	-	-	107	100	-6
L01BB07	nelarabine	-	-	-	0	-	-100
L01BC	Pyrimidine analogues	-	-	-	9 810	81	-32
L01BC01	cytarabine	-	-	-	212	100	-5
L01BC02	fluorouracil	-	-	-	374	100	194
L01BC05	gemcitabine	-	-	-	1 147	100	129
L01BC06	capecitabine	-	-	-	1 221	2	-11
L01BC07	azacitidine	-	-	-	5 935	100	-50
L01BC08	decitabine	-	-	-	231	100	918
L01BC52	fluorouracil, combinations	-	-	-	1	0	-8
L01BC53	tegafur, combinations	-	-	-	144	6	-59
L01BC59	trifluridine, combinations	-	-	-	545	1	2 014
L01C	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	-	-	-	12 949	90	-6
L01CA	Vinca alkaloids and analogues	-	-	-	1 824	37	1
L01CA01	vinblastine	-	-	-	27	100	16
L01CA02	vincristine	-	-	-	140	100	-20
L01CA03	vindesine	-	-	-	5	100	-8
L01CA04	vinorelbine	-	-	-	1 521	25	10
L01CA05	vinflunine	-	-	-	132	100	-38
L01CB	Podophyllotoxin derivatives	-	-	-	336	72	26
L01CB01	etoposide	-	-	-	336	72	26
L01CD	Taxanes	-	-	-	10 145	100	-8

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01CD01	paclitaxel	-	-	-	5 872	100	-14
L01CD02	docetaxel	-	-	-	890	100	9
L01CD04	cabazitaxel	-	-	-	3 383	100	-1
L01CX	Other plant alkaloids and other natural products	-	-	-	644	100	-6
L01CX01	trabectedin	-	-	-	644	100	-6
L01D	CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES	-	-	-	4 308	99	-12
L01DB	Anthracyclines and related substances	-	-	-	3 848	100	-12
L01DB01	doxorubicin	-	-	-	1 933	100	-4
L01DB03	epirubicin	-	-	-	1 343	100	-26
L01DB06	idarubicin	-	-	-	329	100	-22
L01DB07	mitoxantrone	-	-	-	162	100	32
L01DB11	pixantrone	-	-	-	82	100	1 350
L01DC	Other cytotoxic antibiotics	-	-	-	460	96	-16
L01DC01	bleomycin	-	-	-	73	100	7
L01DC03	mitomycin	-	-	-	387	95	-19
L01X	OTHER ANTINEOPLASTIC AGENTS	-	-	-	220 856	73	4
L01XA	Platinum compounds	-	-	-	1 223	100	94
L01XA01	cisplatin	-	-	-	234	100	263
L01XA02	carboplatin	-	-	-	326	99	3
L01XA03	oxaliplatin	-	-	-	662	100	163
L01XC	Monoclonal antibodies	-	-	-	131 780	100	7
L01XC02	rituximab	-	-	-	35 153	100	0
L01XC03	trastuzumab	-	-	-	26 036	100	5
L01XC05	gemtuzumab ozogamicin	-	-	-	14	100	-
L01XC06	cetuximab	-	-	-	2 580	100	21
L01XC07	bevacizumab	-	-	-	24 275	100	9
L01XC08	panitumumab	-	-	-	4 403	100	6
L01XC10	ofatumumab	-	-	-	222	100	79
L01XC11	ipilimumab	-	-	-	170	100	225
L01XC12	brentuximab vedotin	-	-	-	921	100	-66
L01XC13	pertuzumab	-	-	-	9 767	100	23
L01XC14	trastuzumab emtansine	-	-	-	3 734	100	-6
L01XC15	obinutuzumab	-	-	-	1 349	100	-58



## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01XC17	nivolumab	-	-	-	8 200	100	46
L01XC18	pembrolizumab	-	-	-	6 365	100	-13
L01XC19	blinatumomab	-	-	-	363	100	-79
L01XC21	ramucirumab	-	-	-	317	100	112
L01XC22	necitumumab	-	-	-	6	100	0
L01XC23	elotuzumab	-	-	-	63	100	-
L01XC24	daratumumab	-	-	-	5 383	100	193
L01XC26	inotuzumab ozogamicin	-	-	-	339	100	42
L01XC27	olaratumab	-	-	-	1 308	100	343
L01XC32	atezolizumab	-	-	-	813	100	2 517
L01XD	Sensitizers used in photodynamic/radiation therapy	-	-	-	935	100	3
L01XD03	methyl aminolevulinate	-	-	-	698	100	5
L01XD04	aminolevulinic acid	-	-	-	237	100	-2
L01XE	Protein kinase inhibitors	-	-	-	57 737	5	1
L01XE01	imatinib	-	-	-	5 977	1	-14
L01XE02	gefitinib	-	-	-	904	4	-46
L01XE03	erlotinib	-	-	-	1 521	3	-27
L01XE04	sunitinib	-	-	-	5 886	2	-44
L01XE05	sorafenib	-	-	-	2 217	13	-21
L01XE06	dasatinib	-	-	-	2 621	5	-13
L01XE07	lapatinib	-	-	-	618	1	2
L01XE08	nilotinib	-	-	-	2 505	1	6
L01XE09	temsirolimus	-	-	-	34	100	-74
L01XE10	everolimus	-	-	-	1 976	6	11
L01XE11	pazopanib	-	-	-	2 889	1	-1
L01XE12	vandetanib	-	-	-	145	100	18
L01XE13	afatinib	-	-	-	1 106	2	32
L01XE14	bosutinib	-	-	-	436	2	-13
L01XE15	vemurafenib	-	-	-	631	2	-66
L01XE16	crizotinib	-	-	-	1 540	5	-25
L01XE17	axitinib	-	-	-	1 661	0	-51
L01XE18	ruxolitinib	-	-	-	3 818	12	29
L01XE21	regorafenib	-	-	-	1 369	0	-45
L01XE23	dabrafenib	-	-	-	5 147	1	8

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L01XE24	ponatinib	-	-	-	718	18	41
L01XE25	trametinib	-	-	-	1 976	2	-
L01XE26	cabozantinib	-	-	-	1 827	1	4 514
L01XE27	ibrutinib	-	-	-	4 413	5	-
L01XE28	ceritinib	-	-	-	0	-	-100
L01XE29	lenvatinib	-	-	-	375	0	347
L01XE31	nintedanib	-	-	-	3 238	1	55
L01XE33	palbociclib	-	-	-	1 141	1	729
L01XE35	osimertinib	-	-	-	396	62	79
L01XE36	alectinib	-	-	-	41	28	-
L01XE39	midostaurin	-	-	-	610	100	-
L01XX	Other antineoplastic agents	-	-	-	29 182	83	-5
L01XX05	hydroxycarbamide	-	-	-	468	2	0
L01XX11	estramustine	-	-	-	6	2	-71
L01XX14	tretinoin	-	-	-	49	99	-4
L01XX17	topotecan	-	-	-	156	37	-14
L01XX19	irinotecan	-	-	-	653	100	-52
L01XX23	mitotane	-	-	-	256	4	28
L01XX24	pegaspargase	-	-	-	630	99	13
L01XX25	bexarotene	-	-	-	362	100	-41
L01XX27	arsenic trioxide	-	-	-	172	100	11
L01XX32	bortezomib	-	-	-	11 412	100	4
L01XX35	anagrelide	-	-	-	677	1	-73
L01XX41	eribulin	-	-	-	1 182	100	-27
L01XX43	vismodegib	-	-	-	258	5	-24
L01XX44	aflibercept	-	-	-	509	100	-27
L01XX45	carfilzomib	-	-	-	8 673	100	47
L01XX46	olaparib	-	-	-	713	1	3 422
L01XX47	idelalisib	-	-	-	2 351	4	-53
L01XX50	ixazomib	-	-	-	450	71	145
L01XX51	talimogene laherparepvec	-	-	-	0	-	-100
L01XX52	venetoclax	-	-	-	207	49	-
L02	ENDOCRINE THERAPY	7,60	3	2	55 959	3	38
L02A	HORMONES AND RELATED AGENTS	1,72	4	2	11 781	5	0

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L02AB	Progestogens	0,01	7	6	101	7	6
L02AB02	medroxyprogesterone	0,01	7	6	101	7	6
L02AE	Gonadotrophin releasing hormone analogues	1,70	4	2	11 680	5	0
L02AE01	buserelin	0,00	0	-19	28	0	-16
L02AE02	leuprorelin	1,33	5	-1	9 074	5	-2
L02AE03	goserelin	0,20	5	-16	1 409	5	-19
L02AE04	triptorelin	0,17	3	96	1 170	3	75
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS	5,89	3	3	44 178	2	54
L02BA	Anti-estrogens	1,20	2	1	2 946	5	4
L02BA01	tamoxifen	1,07	1	1	551	1	1
L02BA02	toremifene	0,01	1	-5	12	1	-5
L02BA03	fulvestrant	0,13	6	6	2 384	6	5
L02BB	Anti-androgens	1,73	2	1	27 317	1	94
L02BB01	flutamide	0,01	5	-36	36	5	-36
L02BB03	bicalutamide	1,59	2	-3	1 373	2	-7
L02BB04	enzalutamide	0,13	1	107	25 909	1	107
L02BG	Aromatase inhibitors	2,65	2	5	1 166	2	14
L02BG03	anastrozole	0,27	2	-24	173	2	-2
L02BG04	letrozole	2,15	2	8	828	1	18
L02BG06	exemestane	0,24	3	21	165	3	14
L02BX	Other hormone antagonists and related agents	0,31	19	2	12 748	4	18
L02BX02	degarelix	0,26	23	-1	1 969	17	-2
L02BX03	abiraterone	0,05	1	22	10 779	1	22
L03	IMMUNOSTIMULANTS	0,76	5	-50	37 862	14	-42
L03A	IMMUNOSTIMULANTS	0,76	5	-50	37 862	14	-42
L03AA	Colony stimulating factors	0,23	15	-29	19 383	16	-28
L03AA02	filgrastim	0,03	35	-37	3 247	39	-41
L03AA10	lenograstim	0,00	33	-2	28	33	-2
L03AA13	pegfilgrastim	0,11	15	12	9 330	15	12
L03AA14	lipegfilgrastim	0,09	7	-48	6 777	7	-48
L03AB	Interferons	0,43	1	-56	10 496	2	-56
L03AB04	interferon alfa-2a	0,01	1	-5	205	1	-5
L03AB05	interferon alfa-2b	0,03	1	-54	778	1	-54

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L03AB07	interferon beta-1a	0,32	0	-58	6 762	0	-58
L03AB08	interferon beta-1b	0,03	0	-19	1 050	0	-24
L03AB10	peginterferon alfa-2b	0,00	100	-92	21	100	-92
L03AB11	peginterferon alfa-2a	0,00	100	-92	140	100	-92
L03AB13	peginterferon beta-1a	0,03	0	-26	1 540	0	-27
L03AX	Other immunostimulants	0,11	0	-54	7 983	24	-46
L03AX03	BCG vaccine	-	-	-	714	99	4
L03AX13	glatiramer acetate	0,11	0	-54	6 105	0	-55
L03AX16	plerixafor	0,00	100	57	1 165	100	57
L04	IMMUNOSUPPRESSANTS	13,78	15	-4	331 467	30	-17
L04A	IMMUNOSUPPRESSANTS	13,78	15	-4	331 467	30	-17
L04AA	Selective immunosuppressants	1,53	14	5	57 855	35	20
L04AA04	antithymocyte immunoglobulin	0,00	100	1	249	100	1
L04AA06	mycophenolic acid	0,45	4	2	4 577	5	2
L04AA10	sirolimus	0,01	18	-46	159	18	-47
L04AA13	leflunomide	0,49	2	-7	379	2	-18
L04AA18	everolimus	0,00	94	12	89	94	12
L04AA24	abatacept	0,08	42	8	7 914	36	8
L04AA26	belimumab	0,00	100	-29	379	100	-33
L04AA27	fingolimod	0,14	0	16	14 370	0	13
L04AA29	tofacitinib	0,04	3	401	2 357	3	393
L04AA31	teriflunomide	0,12	0	14	6 544	0	10
L04AA32	apremilast	0,04	0	-26	2 257	0	-26
L04AA33	vedolizumab	0,13	100	49	13 688	100	49
L04AA34	alemtuzumab	0,01	97	-68	985	97	-68
L04AA36	ocrelizumab	0,01	100	-	1 700	100	-
L04AA37	baricitinib	0,02	1	-	2 208	2	1 994
L04AB	Tumor necrosis factor alpha (TNF-a) inhibitors	3,41	46	-24	172 902	39	-23
L04AB01	etanercept	0,56	0	-35	26 327	0	-52
L04AB02	infliximab	1,53	100	-13	66 381	100	22
L04AB04	adalimumab	0,77	2	-41	51 988	2	-41
L04AB05	certolizumab pegol	0,10	2	18	6 206	2	17
L04AB06	golimumab	0,45	1	-7	22 001	1	0
L04AC	Interleukin inhibitors	0,65	23	37	34 078	21	31

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
L04AC01	daclizumab	0,00	0	-71	14	0	-73
L04AC02	basiliximab	0,00	100	23	256	100	20
L04AC03	anakinra	0,01	11	3	466	11	3
L04AC05	ustekinumab	0,33	24	45	12 005	17	33
L04AC07	tocilizumab	0,14	49	13	9 001	54	12
L04AC10	secukinumab	0,14	0	32	9 818	0	32
L04AC12	brodalumab	-	-	-	14	0	-
L04AC13	ixekizumab	0,03	0	147	1 923	0	146
L04AC14	sarilumab	0,00	0	-	197	0	-
L04AC16	guselkumab	0,00	0	-	382	0	-
L04AD	Calcineurin inhibitors	0,74	5	8	11 653	5	0
L04AD01	ciclosporin	0,40	4	0	4 933	4	-19
L04AD02	tacrolimus	0,34	5	19	6 721	6	19
L04AX	Other immunosuppressants	7,46	1	2	54 979	4	-39
L04AX01	azathioprine	1,48	1	6	1 078	1	8
L04AX02	thalidomide	0,00	23	-61	101	23	-61
L04AX03	methotrexate	5,67	1	7	7 404	0	15
L04AX04	lenalidomide	0,09	5	-40	26 653	6	-38
L04AX05	pirfenidone	0,03	2	-37	4 277	2	-37
L04AX06	pomalidomide	0,00	23	67	1 851	22	117
L04AX07	dimethyl fumarate	0,19	0	-56	13 614	0	-57
<b>M</b>	<b>MUSCULO-SKELETAL SYSTEM</b>	<b>97,15</b>	<b>2</b>	<b>-1</b>	<b>100 847</b>	<b>23</b>	<b>4</b>
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	77,40	2	0	44 453	2	-9
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	77,28	2	0	44 375	2	-9
M01AB	Acetic acid derivatives and related substances	4,04	2	-26	2 296	7	-29
M01AB01	indometacin	0,19	1	-10	136	1	-3
M01AB05	diclofenac	3,76	2	-27	2 002	5	-31
M01AB15	ketorolac	0,02	81	-2	65	81	-2
M01AB55	diclofenac, combinations	0,07	1	-14	92	1	-13
M01AC	Oxicams	1,25	1	-14	414	1	-15
M01AC06	meloxicam	1,25	1	-14	414	1	-15
M01AE	Propionic acid derivatives	58,44	2	1	32 985	1	-2

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
M01AE01	ibuprofen	49,77	1	1	28 767	1	-1
M01AE02	naproxen	5,90	2	-2	1 906	2	-9
M01AE03	ketoprofen	0,74	1	-8	494	1	-7
M01AE17	dexketoprofen	0,04	88	16	193	83	16
M01AE51	ibuprofen, combinations	0,48	0	-12	742	0	-9
M01AE52	naproxen and esomeprazole	1,51	0	-3	884	0	-3
M01AG	Fenamates	0,22	2	-7	93	3	-8
M01AG01	mefenamic acid	0,04	12	-16	18	17	-16
M01AG02	tolfenamic acid	0,18	0	-5	75	0	-5
M01AH	Coxibs	9,55	1	17	4 013	4	-42
M01AH01	celecoxib	0,67	2	-8	240	2	-25
M01AH04	parecoxib	0,00	99	-46	50	99	-46
M01AH05	etoricoxib	8,89	1	19	3 723	2	-43
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids	3,78	1	-11	4 575	1	-2
M01AX01	nabumetone	0,04	1	-11	18	1	-11
M01AX05	glucosamine	3,74	1	-11	2 111	1	-9
M01AX25	chondroitin sulfate	-	-	-	2 446	0	5
M01C	SPECIFIC ANTIRHEUMATIC AGENTS	0,12	1	-8	78	1	-8
M01CB	Gold preparations	0,12	1	-8	78	1	-8
M01CB01	sodium aurothiomalate	0,12	1	-8	78	1	-8
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	-	-	-	12 945	1	-6
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	-	-	-	12 945	1	-6
M02AA	Antiinflammatory preparations, non-steroids for topical use	-	-	-	11 958	1	-5
M02AA07	piroxicam	-	-	-	898	3	-7
M02AA10	ketoprofen	-	-	-	94	25	-21
M02AA13	ibuprofen	-	-	-	616	0	-
M02AA15	diclofenac	-	-	-	10 350	0	-10
M02AC	Preparations with salicylic acid derivatives	-	-	-	987	5	-10
M03	MUSCLE RELAXANTS	4,68	3	-10	14 344	63	7
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS	-	-	-	10 244	81	9

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
M03AB	Choline derivatives	-	-	-	637	99	29
M03AB01	suxamethonium	-	-	-	637	99	29
M03AC	Other quaternary ammonium compounds	-	-	-	1 911	99	9
M03AC09	rocuronium bromide	-	-	-	1 799	99	10
M03AC10	mivacurium chloride	-	-	-	22	93	-12
M03AC11	cisatracurium	-	-	-	89	100	-6
M03AX	Other muscle relaxants, peripherally acting agents	-	-	-	7 697	75	8
M03AX01	botulinum toxin	-	-	-	7 697	75	8
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS	4,68	3	-10	4 100	20	2
M03BC	Ethers, chemically close to antihistamines	2,25	2	-19	1 078	42	-13
M03BC01	orphenadrine (citrate)	2,00	2	-21	953	48	-15
M03BC51	orphenadrine, combinations	0,26	1	0	125	1	1
M03BX	Other centrally acting agents	2,42	3	0	3 022	12	9
M03BX01	baclofen	0,51	8	11	818	38	64
M03BX02	tizanidine	1,91	2	-2	2 203	2	-3
M04	ANTIGOUT PREPARATIONS	3,99	2	8	1 941	3	9
M04A	ANTIGOUT PREPARATIONS	3,99	2	8	1 941	3	9
M04AA	Preparations inhibiting uric acid production	3,98	2	8	1 904	2	8
M04AA01	allopurinol	3,75	2	7	1 501	2	7
M04AA03	febuxostat	0,23	4	18	403	4	13
M04AC	Preparations with no effect on uric acid metabolism	0,02	15	46	37	15	46
M04AC01	colchicine	0,02	15	46	37	15	46
M05	DRUGS FOR TREATMENT OF BONE DISEASES	11,01	5	-1	16 114	14	0
M05B	DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	11,01	5	-1	16 114	14	0
M05BA	Bisphosphonates	3,58	2	-5	3 083	44	-11
M05BA02	clodronic acid	0,02	1	-27	167	1	-33
M05BA03	pamidronic acid	0,00	100	-51	91	100	-51
M05BA04	alendronic acid	2,31	2	-3	946	2	2
M05BA06	ibandronic acid	0,59	2	-11	261	8	-14
M05BA07	risedronic acid	0,66	3	-8	389	4	-4
M05BA08	zoledronic acid	0,01	99	-31	1 229	98	-11
M05BB	Bisphosphonates, combinations	0,22	1	-64	264	1	-64

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
M05BB03	alendronic acid and colecalciferol	0,22	1	-64	264	1	-64
M05BC	Bone morphogenetic proteins	-	-	-	40	100	30
M05BC01	dibotermin alfa	-	-	-	40	100	30
M05BX	Other drugs affecting mineralization	7,21	7	7	12 727	6	8
M05BX03	strontium ranelate	0,00	100	-100	0	100	-100
M05BX04	denosumab	7,21	7	8	12 727	6	8
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	0,07	73	-3	11 051	98	244
M09A	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	0,07	73	-3	11 051	98	244
M09AB	Enzymes	0,00	97	4	1 021	97	4
M09AB02	collagenase clostridium histolyticum	0,00	97	4	1 021	97	4
M09AX	Other drugs for disorders of the musculo-skeletal system	0,07	73	-3	10 029	98	350
M09AX01	hyaluronic acid	0,07	71	-8	613	71	-16
M09AX07	nusinersen	0,00	100	-	9 416	100	528
<b>N</b>	<b>NERVOUS SYSTEM</b>	<b>269,18</b>	<b>8</b>	<b>0</b>	<b>342 599</b>	<b>29</b>	<b>-10</b>
N01	ANESTHETICS	-	-	-	19 720	89	2
N01A	ANESTHETICS, GENERAL	-	-	-	10 396	96	7
N01AB	Halogenated hydrocarbons	-	-	-	3 136	98	3
N01AB06	isoflurane	-	-	-	10	100	9
N01AB07	desflurane	-	-	-	698	100	10
N01AB08	sevoflurane	-	-	-	2 428	97	2
N01AF	Barbiturates, plain	-	-	-	108	99	20
N01AF03	thiopental	-	-	-	108	99	20
N01AH	Opioid anesthetics	-	-	-	1 708	95	9
N01AH01	fentanyl	-	-	-	222	98	-3
N01AH02	alfentanil	-	-	-	167	93	-5
N01AH03	sufentanil	-	-	-	37	100	-31
N01AH06	remifentanil	-	-	-	1 282	94	15
N01AX	Other general anesthetics	-	-	-	5 444	96	9
N01AX03	ketamine	-	-	-	52	88	57
N01AX10	propofol	-	-	-	4 144	96	7
N01AX14	esketamine	-	-	-	1 247	96	15



## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N01B	ANESTHETICS, LOCAL	-	-	-	9 324	80	-4
N01BB	Amides	-	-	-	8 905	80	-4
N01BB01	bupivacaine	-	-	-	878	90	-12
N01BB02	lidocaine	-	-	-	1 849	81	-18
N01BB03	mepivacaine	-	-	-	5	19	-22
N01BB09	ropivacaine	-	-	-	1 453	96	10
N01BB10	levobupivacaine	-	-	-	983	99	2
N01BB20	combinations	-	-	-	1 099	51	1
N01BB51	bupivacaine, combinations	-	-	-	39	88	-17
N01BB52	lidocaine, combinations	-	-	-	1 082	82	1
N01BB54	prilocaine, combinations	-	-	-	145	61	-7
N01BB58	articaine, combinations	-	-	-	1 372	67	-1
N01BX	Other local anesthetics	-	-	-	419	90	-2
N01BX04	capsaicin	-	-	-	419	90	-2
N02	ANALGESICS	54,50	6	0	63 175	16	-5
N02A	OPIOIDS	13,91	9	-5	27 304	24	-12
N02AA	Natural opium alkaloids	2,33	35	0	10 431	50	-5
N02AA01	morphine	0,29	84	-7	1 646	86	8
N02AA03	hydromorphone	0,09	55	-27	511	63	-33
N02AA05	oxycodone	1,68	25	3	4 924	48	-3
N02AA55	oxycodone and naloxone	0,27	36	-1	3 349	34	-6
N02AB	Phenylpiperidine derivatives	0,83	20	-7	3 838	20	-11
N02AB03	fentanyl	0,83	20	-7	3 838	20	-11
N02AE	Oripavine derivatives	1,38	6	8	5 231	6	-26
N02AE01	buprenorphine	1,38	6	8	5 231	6	-26
N02AJ	Opioids in combination with non-opioid analgesics	6,75	1	-9	3 904	1	-15
N02AJ06	codeine and paracetamol	6,32	2	-11	3 307	1	-17
N02AJ08	codeine and ibuprofen	0,14	0	-13	341	0	-29
N02AJ13	tramadol and paracetamol	0,29	1	93	251	1	78
N02AJ14	taramadol and dexketoprofen	-	-	-	5	0	338
N02AX	Other opioids	2,62	2	-5	3 899	4	-6
N02AX02	tramadol	2,62	2	-5	3 899	4	-6
N02B	OTHER ANALGESICS AND ANTIPYRETICS	38,30	5	1	29 358	10	-1
N02BA	Salicylic acid and derivatives	1,68	0	-10	4 569	0	-8

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N02BA01	acetylsalicylic acid	0,83	1	-12	1 142	1	-22
N02BA51	acetylsalicylic acid, combinations excl. psycholeptics	0,85	0	-8	3 427	0	-2
N02BE	Anilides	36,62	6	2	24 665	12	0
N02BE01	paracetamol	36,46	6	2	24 190	12	0
N02BE51	paracetamol, combinations excl. psycholeptics	0,16	0	-7	475	0	3
N02BG	Other analgesics and antipyretics	-	-	-	123	17	29
N02BG09	methoxyflurane	-	-	-	2	100	-
N02BG10	cannabinoids	-	-	-	121	16	27
N02C	ANTIMIGRAINE PREPARATIONS	2,29	1	7	6 513	7	15
N02CC	Selective 5HT1-receptor agonists	2,29	1	7	6 006	1	6
N02CC01	sumatriptan	1,49	1	10	2 793	2	21
N02CC02	naratriptan	0,02	0	-4	152	0	-7
N02CC03	zolmitriptan	0,19	1	-12	817	1	-19
N02CC04	rizatriptan	0,13	0	11	645	0	7
N02CC05	almotriptan	0,10	0	7	437	0	5
N02CC06	eletriptan	0,20	0	11	592	0	0
N02CC07	frovatriptan	0,15	0	10	570	0	3
N02CX	Other antimigraine preparations	-	-	-	507	79	-
N02CX07	erenumab	-	-	-	507	79	-
N03	ANTIEPILEPTICS	22,23	4	-13	54 748	9	-24
N03A	ANTIEPILEPTICS	22,23	4	-13	54 748	9	-24
N03AB	Hydantoin derivatives	0,19	10	-8	907	86	-26
N03AB02	phenytoin	0,18	7	-7	138	7	-7
N03AB05	fosphenytoin	0,01	100	-29	769	100	-29
N03AE	Benzodiazepine derivatives	0,74	2	-6	533	3	-5
N03AE01	clonazepam	0,74	2	-6	533	3	-5
N03AF	Carboxamide derivatives	3,66	3	0	4 912	4	1
N03AF01	carbamazepine	1,40	3	-3	1 246	9	1
N03AF02	oxcarbazepine	2,20	3	2	3 073	3	2
N03AF03	rufinamide	0,01	5	-44	204	6	-44
N03AF04	eslicarbazepine	0,05	3	43	389	3	41
N03AG	Fatty acid derivatives	3,57	6	-2	4 795	11	0
N03AG01	valproic acid	3,56	6	-2	4 707	11	0

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N03AG04	vigabatrin	0,02	10	-3	89	10	-3
N03AX	Other antiepileptics	14,07	4	-19	43 600	8	-28
N03AX09	lamotrigine	2,12	3	4	4 830	3	-1
N03AX11	topiramate	0,37	5	0	1 635	5	-1
N03AX12	gabapentin	3,12	5	17	6 005	5	10
N03AX14	levetiracetam	2,53	7	5	8 229	12	-3
N03AX15	zonisamide	0,20	2	-49	920	3	-52
N03AX16	pregabalin	5,19	3	-43	16 541	4	-51
N03AX17	stiripentol	0,01	3	6	293	3	3
N03AX18	lacosamide	0,45	8	24	4 183	23	21
N03AX21	retigabine	-	-	-100	0	-	-100
N03AX22	perampanel	0,06	5	-24	737	7	-27
N03AX23	brivaracetam	0,03	9	131	226	29	75
N04	ANTI-PARKINSON DRUGS	5,09	4	-1	18 634	4	-4
N04A	ANTICHOLINERGIC AGENTS	0,18	5	-7	102	5	-7
N04AA	Tertiary amines	0,18	5	-7	102	5	-7
N04AA02	biperiden	0,18	5	-7	102	5	-7
N04B	DOPAMINERGIC AGENTS	4,91	4	-1	18 532	4	-4
N04BA	Dopa and dopa derivatives	2,27	6	-2	13 417	5	0
N04BA02	levodopa and decarboxylase inhibitor	1,56	6	-3	11 295	5	1
N04BA03	levodopa, decarboxylase inhibitor and COMT inhibitor	0,72	6	1	2 122	6	-6
N04BC	Dopamine agonists	1,47	2	3	4 318	3	-8
N04BC01	bromocriptine	0,00	19	-1	8	19	-1
N04BC04	ropinirole	0,69	2	2	821	2	-18
N04BC05	pramipexole	0,67	2	5	2 694	2	-6
N04BC06	cabergoline	0,01	5	-3	68	5	-3
N04BC07	apomorphine	0,00	2	-5	119	2	-5
N04BC09	rotigotine	0,09	4	2	609	4	1
N04BD	Monoamine oxidase type B inhibitors	1,13	3	-5	615	4	-32
N04BD01	selegiline	0,75	3	-7	356	3	-8
N04BD02	rasagiline	0,38	3	0	257	5	-50
N04BD03	safinamide	0,00	6	70	2	8	36
N04BX	Other dopaminergic agents	0,03	7	-17	182	7	-18

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N04BX01	tolcapone	-	-	-100	0	-	-100
N04BX02	entacapone	0,03	7	-17	182	7	-17
N05	PSYCHOLEPTICS	73,18	5	0	68 905	14	-10
N05A	ANTIPSYCHOTICS	21,87	7	0	49 954	11	-10
N05AA	Phenothiazines with aliphatic side chain	0,34	7	-7	361	7	-7
N05AA02	levomepromazine	0,34	7	-7	361	7	-7
N05AB	Phenothiazines with piperazine structure	0,45	5	-5	573	5	-4
N05AB02	fluphenazine	-	-	-100	0	-	-100
N05AB03	perphenazine	0,44	5	-4	550	6	-3
N05AB04	prochlorperazine	0,01	2	-10	22	2	-10
N05AC	Phenothiazines with piperidine structure	0,01	4	-75	8	5	-72
N05AC01	periciazine	0,01	4	-75	8	5	-72
N05AD	Butyrophenone derivatives	0,44	23	-4	523	47	-3
N05AD01	haloperidol	0,42	20	-4	371	27	-3
N05AD08	droperidol	0,02	96	-3	152	96	-3
N05AE	Indole derivatives	0,29	7	2	1 304	8	6
N05AE03	sertindole	0,07	6	-8	431	6	-7
N05AE04	ziprasidone	0,17	4	-8	611	5	-8
N05AE05	lurasidone	0,05	18	140	262	17	146
N05AF	Thioxanthene derivatives	0,70	8	-7	621	12	-3
N05AF01	flupentixol	0,06	4	-4	71	3	8
N05AF03	chlorprothixene	0,26	3	-8	267	3	-5
N05AF05	zuclopenthixol	0,38	12	-7	283	22	-3
N05AH	Diazepines, oxazepines, thiazepines and oxepines	13,84	7	2	20 757	12	-9
N05AH01	loxapine	0,00	100	-77	5	100	-77
N05AH02	clozapine	2,30	9	-1	4 953	9	-5
N05AH03	olanzapine	6,22	9	5	11 605	16	1
N05AH04	quetiapine	5,30	4	1	4 070	4	-32
N05AH05	asenapine	0,02	13	-16	125	15	-14
N05AL	Benzamides	0,05	9	-6	109	9	-6
N05AL01	sulpiride	0,05	9	-6	109	9	-6
N05AN	Lithium	0,97	6	3	607	6	3
N05AN01	lithium	0,97	6	3	607	6	3
N05AX	Other antipsychotics	4,79	7	-6	25 094	10	-11

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N05AX08	risperidone	1,91	6	2	10 159	6	-6
N05AX12	aripiprazole	2,39	7	-14	6 946	13	-32
N05AX13	paliperidone	0,48	13	15	7 987	12	11
N05AX15	cariprazine	0,00	64	-	1	50	-
N05B	ANXIOLYTICS	17,44	6	-7	6 382	12	-9
N05BA	Benzodiazepine derivatives	15,96	6	-8	5 065	13	-11
N05BA01	diazepam	4,70	9	-11	1 650	33	-22
N05BA02	chlordiazepoxide	0,19	14	-65	54	13	-59
N05BA04	oxazepam	4,92	4	-3	1 767	3	-2
N05BA06	lorazepam	1,90	10	-2	402	8	0
N05BA09	clobazam	0,36	4	6	121	4	6
N05BA12	alprazolam	3,88	1	-6	1 071	1	-5
N05BB	Diphenylmethane derivatives	1,25	6	-5	752	5	-9
N05BB01	hydroxyzine	1,25	6	-5	752	5	-9
N05BE	Azaspirodecanedione derivatives	0,23	9	9	565	9	10
N05BE01	buspirone	0,23	9	9	565	9	10
N05C	HYPNOTICS AND SEDATIVES	33,86	4	3	12 570	28	-11
N05CD	Benzodiazepine derivatives	6,78	5	-8	3 357	13	2
N05CD02	nitrazepam	0,33	3	-18	106	2	-10
N05CD05	triazolam	0,03	1	-26	38	1	-26
N05CD07	temazepam	6,20	4	-7	1 863	3	-2
N05CD08	midazolam	0,22	44	-3	1 351	27	12
N05CF	Benzodiazepine related drugs	17,78	2	-7	2 668	2	-9
N05CF01	zopiclone	12,97	3	-8	2 017	2	-9
N05CF02	zolpidem	4,81	1	-4	652	1	-9
N05CH	Melatonin receptor agonists	9,08	6	53	3 413	6	6
N05CH01	melatonin	9,08	6	53	3 413	6	6
N05CM	Other hypnotics and sedatives	0,23	6	-23	3 131	90	-35
N05CM09	Valerianae radix	0,21	0	-22	309	0	-26
N05CM18	dexmedetomidine	0,01	100	-36	2 822	100	-35
N06	PSYCHOANALEPTICS	96,12	2	5	49 995	3	-4
N06A	ANTIDEPRESSANTS	74,77	2	6	31 412	2	3
N06AA	Non-selective monoamine reuptake inhibitors	4,35	2	2	3 309	2	5
N06AA04	clomipramine	0,20	3	-1	147	3	-1

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N06AA06	trimipramine	0,10	4	3	73	4	3
N06AA09	amitriptyline	3,01	2	2	2 364	2	3
N06AA10	nortriptyline	0,55	3	4	392	2	22
N06AA12	doxepin	0,48	3	-1	332	3	2
N06AB	Selective serotonin reuptake inhibitors	41,20	2	3	6 635	2	-19
N06AB03	fluoxetine	4,14	2	4	971	2	3
N06AB04	citalopram	9,47	2	-9	1 568	2	-27
N06AB05	paroxetine	2,32	1	0	716	1	-1
N06AB06	sertraline	8,64	2	10	1 582	2	-36
N06AB08	fluvoxamine	0,15	1	-5	83	1	-5
N06AB10	escitalopram	16,47	2	8	1 714	3	-6
N06AG	Monoamine oxidase type A inhibitors	0,35	1	0	271	1	1
N06AG02	moclobemide	0,35	1	0	271	1	1
N06AX	Other antidepressants	28,88	2	11	21 198	3	12
N06AX03	mianserin	0,30	2	4	273	2	7
N06AX05	trazodone	0,16	3	1	139	3	1
N06AX11	mirtazapine	8,09	4	2	4 239	5	4
N06AX12	bupropion	2,08	1	13	3 670	1	12
N06AX16	venlafaxine	11,27	2	12	6 341	2	12
N06AX17	milnacipran	0,05	2	-48	68	2	-47
N06AX18	reboxetin	0,03	1	-1	33	1	-2
N06AX21	duloxetine	3,61	2	10	1 147	3	-20
N06AX22	agomelatine	0,77	3	11	1 240	3	9
N06AX25	Hyperici herba	-	-	-	0	-	-100
N06AX26	vortioxetine	2,53	3	50	4 049	3	49
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	4,60	1	5	11 432	4	0
N06BA	Centrally acting sympathomimetics	4,55	1	6	11 106	1	1
N06BA02	dexamfetamine	0,11	0	25	540	0	22
N06BA04	methylphenidate	3,69	1	10	6 086	1	5
N06BA07	modafinil	0,08	0	15	712	1	15
N06BA09	atomoxetine	0,16	5	17	1 588	5	15
N06BA12	lisdexamfetamine	0,52	1	-20	2 179	1	-20
N06BC	Xanthine derivatives	0,00	99	-8	275	99	-8

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N06BC01	caffeine	0,00	99	-8	275	99	-8
N06BX	Other psychostimulants and nootropics	0,05	4	-51	52	4	-51
N06BX03	piracetam	0,05	4	-51	52	4	-51
N06C	PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION	0,78	1	-4	468	1	-4
N06CA	Antidepressants in combination with psycholeptics	0,78	1	-4	468	1	-4
N06CA01	amitriptyline and psycholeptics	0,78	1	-4	468	1	-4
N06D	ANTI-DEMENTIA DRUGS	15,98	5	1	6 681	6	-30
N06DA	Anticholinesterases	9,39	5	0	5 134	6	-35
N06DA02	donepezil	6,27	4	0	411	3	-21
N06DA03	rivastigmine	1,56	7	-5	3 468	7	-41
N06DA04	galantamine	1,56	4	4	1 255	4	-17
N06DX	Other anti-dementia drugs	6,59	6	3	1 547	6	-4
N06DX01	memantine	6,59	6	3	1 547	6	-4
N07	OTHER NERVOUS SYSTEM DRUGS	18,06	67	-1	67 422	80	-12
N07A	PARASYMPATHOMIMETICS	0,25	6	5	471	44	-3
N07AA	Anticholinesterases	0,25	6	5	459	45	-2
N07AA02	pyridostigmine	0,24	3	6	255	3	6
N07AA51	neostigmine, combinations	0,01	98	-8	204	98	-10
N07AX	Other parasympathomimetics	0,00	4	-27	13	4	-27
N07AX01	pilocarpine	0,00	4	-27	13	4	-27
N07B	DRUGS USED IN ADDICTIVE DISORDERS	15,04	80	-1	64 651	83	-11
N07BA	Drugs used in nicotine dependence	13,40	84	4	60 704	84	-8
N07BA01	nicotine	12,83	88	8	57 716	88	-5
N07BA03	varenicline	0,57	0	-46	2 987	0	-47
N07BB	Drugs used in alcohol dependence	0,66	6	-47	658	5	-40
N07BB01	disulfiram	0,56	6	-51	417	6	-51
N07BB04	naltrexone	0,09	5	1	150	5	0
N07BB05	nalmefene	0,01	2	-10	91	3	-10
N07BC	Drugs used in opioid dependence	0,98	77	-10	3 289	80	-39
N07BC01	buprenorphine	0,00	95	-31	17	95	-31
N07BC02	methadone	0,56	86	43	1 427	91	48
N07BC51	buprenorphine, combinations	0,42	67	-39	1 846	71	-59
N07C	ANTIVERTIGO PREPARATIONS	2,71	1	1	699	1	-7

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
N07CA	Antivertigo preparations	2,71	1	1	699	1	-7
N07CA01	betahistine	2,71	1	1	699	1	-7
N07CA52	cinnarizine, combinations	-	-	-	0	0	-64
N07X	OTHER NERVOUS SYSTEM DRUGS	0,05	4	-22	1 601	2	-37
N07XX	Other nervous system drugs	0,05	4	-22	1 601	2	-37
N07XX02	riluzole	0,02	6	15	208	6	11
N07XX04	sodium oxybate	0,02	1	-43	1 231	1	-43
N07XX06	tetrabenazine	0,01	10	20	83	10	20
N07XX07	fampridine	0,00	5	-21	79	8	-36
<b>P</b>	<b>ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</b>	<b>2,35</b>	<b>3</b>	<b>2</b>	<b>6 224</b>	<b>3</b>	<b>-2</b>
P01	ANTIPROTOZOALS	2,11	3	2	3 315	4	-3
P01A	AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES	0,32	13	-5	828	9	-5
P01AB	Nitroimidazole derivatives	0,32	13	-5	828	9	-5
P01AB01	metronidazole	0,32	13	-5	828	9	-5
P01B	ANTIMALARIALS	1,79	1	3	2 487	3	-2
P01BA	Aminoquinolines	1,75	1	3	1 555	1	3
P01BA02	hydroxychloroquine	1,75	1	3	1 555	1	3
P01BB	Biguanides	0,03	6	8	798	7	-2
P01BB51	proguanil, combinations	0,03	6	8	798	7	-2
P01BC	Quinine alkaloids	0,01	0	-38	134	0	-39
P01BC02	mefloquine	0,01	0	-38	134	0	-39
P02	ANTHELMINTICS	0,25	0	1	1 428	0	1
P02C	ANTINEMATODAL AGENTS	0,25	0	1	1 428	0	1
P02CX	Other antinematodals	0,25	0	1	1 428	0	1
P02CX01	pyrvinium	0,25	0	1	1 428	0	1
P03	ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS	-	-	-	1 481	4	-1
P03A	ECTOPARASITICIDES, INCL. SCABICIDES	-	-	-	1 481	4	-1
P03AC	Pyrethrines, incl. synthetic compounds	-	-	-	1 481	4	0
P03AC04	permethrin	-	-	-	1 481	4	0
P03AX	Other ectoparasiticides, incl. scabicides	-	-	-	0	-	-100
P03AX03	malathion	-	-	-	0	-	-100



## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
<b>R</b>	<b>RESPIRATORY SYSTEM</b>	<b>182,12</b>	<b>2</b>	<b>-1</b>	<b>154 155</b>	<b>6</b>	<b>-6</b>
R01	NASAL PREPARATIONS	35,49	1	-9	24 826	1	-4
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	33,52	1	-9	19 048	1	-7
R01AA	Sympathomimetics, plain	10,74	1	1	4 874	1	4
R01AA05	oxymetazoline	0,78	0	-32	267	0	-30
R01AA07	xylometazoline	9,96	1	5	4 607	1	7
R01AB	Sympathomimetics, combinations excl. corticosteroids	0,80	0	-2	540	0	0
R01AB06	xylometazoline	0,80	0	-2	540	0	0
R01AC	Antiallergic agents, excl. corticosteroids	0,35	1	-15	314	0	-8
R01AC01	cromoglicic acid	0,20	1	-34	144	1	-36
R01AC02	levocabastine	0,07	0	58	104	0	58
R01AC03	azelastine	0,07	0	33	67	0	37
R01AD	Corticosteroids	21,26	1	-12	12 888	1	-10
R01AD01	beclometasone	1,13	0	1	549	0	3
R01AD05	budesonide	0,52	0	-12	225	0	-20
R01AD08	fluticasone	4,18	2	4	2 223	2	3
R01AD09	mometasone	6,35	1	5	2 531	1	7
R01AD11	triamcinolone	0,60	0	24	479	0	32
R01AD12	fluticasone furoate	4,67	0	-47	2 841	0	-47
R01AD58	fluticasone, combinations	3,81	1	24	4 039	1	23
R01AX	Other nasal preparations	0,38	4	-63	432	8	-33
R01AX02	retinol	-	-	-100	0	-	-100
R01AX03	ipratropium bromide	0,11	7	3	159	7	1
R01AX06	mupirocin	-	-	-	130	16	-10
R01AX10	various	0,26	2	-7	143	2	-7
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE	1,97	2	-4	5 779	1	6
R01BA	Sympathomimetics	1,97	2	-4	5 779	1	6
R01BA01	phenylpropanolamine	0,14	6	-2	55	6	-3
R01BA52	pseudoephedrine, combinations	1,83	1	-4	5 724	1	6
R02	THROAT PREPARATIONS	3,68	0	6	7 938	0	11
R02A	THROAT PREPARATIONS	3,68	0	6	7 938	0	11
R02AA	Antiseptics	1,61	0	-1	4 241	0	8

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
R02AA03	dichlorobenzyl alcohol	1,57	0	0	3 568	0	5
R02AA05	chlorhexidine	0,03	3	-33	47	3	-32
R02AA20	various	-	-	-	626	0	44
R02AB	Antibiotics	1,38	1	13	2 456	1	12
R02AB30	gramicidin	1,38	1	13	2 456	1	12
R02AX	Other throat preparations	0,70	0	12	1 242	0	18
R02AX01	flurbiprofen	0,06	0	56	285	0	69
R02AX03	benzydamine	0,64	0	8	956	0	8
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	78,12	3	-2	93 551	8	-9
R03A	ADRENERGICS, INHALANTS	43,45	3	-4	56 601	3	-13
R03AC	Selective beta-2-adrenoceptor agonists	14,77	3	3	8 071	2	0
R03AC02	salbutamol	12,28	3	5	5 635	3	3
R03AC03	terbutaline	1,20	1	3	555	1	3
R03AC12	salmeterol	0,36	1	-7	520	1	-7
R03AC13	formoterol	0,68	1	-6	1 001	1	-6
R03AC18	indacaterol	0,17	2	-20	229	3	-19
R03AC19	olodaterol	0,08	3	-19	132	3	-19
R03AK	Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics	26,71	2	-6	42 950	3	-15
R03AK06	salmeterol and fluticasone	7,50	4	-5	17 977	4	-11
R03AK07	formoterol and budesonide	13,53	1	2	14 932	1	-5
R03AK08	formoterol and beclometasone	2,46	2	21	3 164	2	24
R03AK10	vilanterol and fluticasone furoate	1,91	1	-53	4 710	1	-55
R03AK11	formoterol and fluticasone	1,30	2	16	2 168	2	15
R03AL	Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids	1,97	11	-18	5 579	10	-7
R03AL01	fenoterol and ipratropium bromide	0,48	7	-5	294	18	-3
R03AL02	salbutamol and ipratropium bromide	0,29	50	10	627	51	-10
R03AL03	vilanterol and umeclidinium bromide	0,35	3	-50	1 049	3	-50
R03AL04	indacaterol and glycopyrronium bromide	0,18	3	-15	523	3	-24
R03AL05	formoterol and aclidinium bromide	0,07	2	-19	205	2	-27
R03AL06	olodaterol and tiotropium bromide	0,60	5	-8	1 759	5	-9
R03AL08	vilanterol, umeclidinium bromide and fluticasone furoate	-	-	-	507	3	-

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
R03AL09	formoterol, glycopyrronium bromide and beclometasone	-	-	-	615	4	106 844
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS	26,04	4	-2	29 659	4	-6
R03BA	Glucocorticoids	19,27	2	1	18 017	3	-1
R03BA01	beclometasone	2,54	2	-3	2 487	2	-4
R03BA02	budesonide	4,67	3	-2	4 684	6	-3
R03BA05	fluticasone	5,53	3	-1	7 447	3	-2
R03BA07	mometasone	0,20	1	-7	190	1	-8
R03BA08	ciclesonide	6,34	1	9	3 208	1	10
R03BB	Anticholinergics	6,77	8	-9	11 642	5	-13
R03BB01	ipratropium bromide	0,62	48	6	277	41	6
R03BB04	tiotropium bromide	5,75	4	-6	10 503	4	-9
R03BB05	acridinium bromide	0,05	2	-16	98	2	-16
R03BB06	glycopyrronium bromide	0,11	2	-17	232	2	-17
R03BB07	umeclidinium bromide	0,25	2	-54	532	2	-54
R03BC	Antiallergic agents, excl. corticosteroids	-	-	-100	0	-	-100
R03BC01	cromoglicic acid	-	-	-100	0	-	-100
R03BC03	nedocromil	-	-	-100	0	-	-100
R03C	ADRENERGICS FOR SYSTEMIC USE	0,04	3	-33	98	2	-30
R03CC	Selective beta-2-adrenoceptor agonists	0,04	3	-33	98	2	-30
R03CC02	salbutamol	0,04	3	-33	98	2	-30
R03D	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	8,60	2	3	7 194	68	15
R03DA	Xanthines	0,76	3	-10	288	3	-9
R03DA04	theophylline	0,74	3	-10	211	4	-11
R03DA05	aminophylline	0,01	4	-20	3	4	-20
R03DA54	theophylline, combinations excl. psycholeptics	0,02	1	-7	74	1	-2
R03DC	Leukotriene receptor antagonists	7,67	1	4	1 383	1	-15
R03DC01	zafirlukast	0,02	2	-71	30	2	-71
R03DC03	montelukast	7,65	1	5	1 352	1	-12
R03DX	Other systemic drugs for obstructive airway diseases	0,16	41	9	5 523	88	28
R03DX05	omalizumab	0,04	85	22	2 875	85	19

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
R03DX07	roflumilast	0,09	6	-5	236	7	-5
R03DX08	reslizumab	0,00	100	-	424	100	11
R03DX09	mepolizumab	0,02	100	50	1 881	100	50
R03DX10	benralizumab	0,00	100	-	106	100	-
R05	COUGH AND COLD PREPARATIONS	5,38	2	-1	12 033	2	-3
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS	2,79	3	-3	4 461	4	-4
R05CA	Expectorants	0,17	0	-29	248	0	-21
R05CA03	guaifenesin	0,06	0	-9	81	0	-8
R05CA10	combinations	0,11	0	-38	167	0	-26
R05CB	Mucolytics	2,62	3	-1	4 212	4	-3
R05CB01	acetylcysteine	0,67	3	-2	763	4	-1
R05CB02	bromhexine	1,14	0	-3	1 514	0	-3
R05CB03	carbocisteine	0,06	0	-10	108	0	-9
R05CB06	ambroxol	0,24	3	-3	608	3	-12
R05CB13	dornase alfa (desoxyribonuclease)	0,01	7	3	305	7	0
R05CB15	erdosteine	0,50	11	8	914	10	4
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS	1,15	1	-2	2 322	1	2
R05DA	Opium alkaloids and derivatives	0,96	1	-3	1 742	1	1
R05DA01	ethylmorphine	0,23	1	1	655	1	10
R05DA09	dextromethorphan	0,73	1	-5	1 087	1	-4
R05DB	Other cough suppressants	0,19	0	5	580	0	5
R05DB05	pentoxyverine	0,19	0	5	580	0	5
R05F	COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS	1,44	1	3	4 541	1	8
R05FA	Opium derivatives and expectorants	0,88	1	-5	2 565	1	-2
R05FA02	opium derivatives and expectorants	0,88	1	-5	2 565	1	-2
R05FB	Other cough suppressants and expectorants	0,56	0	20	1 976	0	25
R05FB02	cough suppressants and expectorants	0,56	0	20	1 976	0	25
R05X	OTHER COLD PREPARATIONS	-	-	-	709	0	-44
R06	ANTIHISTAMINES FOR SYSTEMIC USE	59,45	1	6	14 922	1	-3
R06A	ANTIHISTAMINES FOR SYSTEMIC USE	59,45	1	6	14 922	1	-3
R06AA	Aminoalkyl ethers	0,06	1	62	81	2	48

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
R06AA09	doxylamine	0,06	1	62	81	2	48
R06AE	Piperazine derivatives	32,45	2	4	8 032	1	-2
R06AE03	cyclizine	0,05	0	-33	94	0	-33
R06AE05	meclozine	0,15	0	4	349	0	4
R06AE07	cetirizine	27,51	2	4	6 122	1	-1
R06AE09	levocetirizine	4,74	0	4	1 468	0	-2
R06AX	Other antihistamines for systemic use	26,93	0	8	6 809	0	-6
R06AX13	loratadine	3,26	1	5	687	1	4
R06AX18	acrivastine	0,13	0	-12	157	0	-7
R06AX22	ebastine	7,48	0	10	2 237	0	8
R06AX26	fexofenadine	3,10	0	11	1 431	0	11
R06AX27	desloratadine	12,61	0	7	2 138	1	-26
R06AX28	rupatadine	0,00	0	-72	0	0	-72
R06AX29	bilastine	0,35	0	5	157	0	6
R07	OTHER RESPIRATORY SYSTEM PRODUCTS	0,00	100	-1	884	100	1
R07A	OTHER RESPIRATORY SYSTEM PRODUCTS	0,00	100	-1	884	100	1
R07AA	Lung surfactants	0,00	100	-1	884	100	1
R07AA02	natural phospholipids	0,00	100	-1	884	100	1
<b>S</b>	<b>SENSORY ORGANS</b>	<b>27,98</b>	<b>2</b>	<b>7</b>	<b>58 860</b>	<b>43</b>	<b>8</b>
S01	OPHTHALMOLOGICALS	27,98	2	7	56 831	45	8
S01A	ANTIINFECTIVES	-	-	-	4 501	13	2
S01AA	Antibiotics	-	-	-	3 815	13	5
S01AA01	chloramphenicol	-	-	-	3 223	13	5
S01AA12	tobramycin	-	-	-	9	28	-34
S01AA13	fusidic acid	-	-	-	459	5	7
S01AA26	azithromycin	-	-	-	58	0	2
S01AA27	cefuroxime	-	-	-	66	91	22
S01AD	Antivirals	-	-	-	35	8	-10
S01AD03	aciclovir	-	-	-	35	8	-10
S01AE	Fluoroquinolones	-	-	-	650	12	-13
S01AE01	ofloxacin	-	-	-	127	19	-47
S01AE05	levofloxacin	-	-	-	510	10	2
S01AE07	moxifloxacin	-	-	-	13	17	6
S01B	ANTIINFLAMMATORY AGENTS	-	-	-	3 445	42	1

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
S01BA	Corticosteroids, plain	-	-	-	2 815	51	0
S01BA01	dexamethasone	-	-	-	1 434	78	1
S01BA02	hydrocortisone	-	-	-	57	0	1 748
S01BA04	prednisolone	-	-	-	814	4	-14
S01BA05	triamcinolone	-	-	-	278	100	5
S01BA07	fluorometholone	-	-	-	232	1	23
S01BC	Antiinflammatory agents, non-steroids	-	-	-	630	5	5
S01BC03	diclofenac	-	-	-	91	28	14
S01BC05	ketorolac	-	-	-	6	14	-9
S01BC10	nepafenac	-	-	-	497	1	2
S01BC11	bromfenac	-	-	-	37	0	42
S01C	ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	-	-	-	1 068	19	-20
S01CA	Corticosteroids and antiinfectives in combination	-	-	-	1 068	19	-20
S01CA01	dexamethasone and antiinfectives	-	-	-	808	23	2
S01CA03	hydrocortisone and antiinfectives	-	-	-	260	8	-51
S01E	ANTI GLAUCOMA PREPARATIONS AND MIOTICS	27,98	2	7	14 532	3	1
S01EA	Sympathomimetics in glaucoma therapy	0,67	8	-7	449	26	-4
S01EA03	apraclonidine	0,04	63	4	133	75	4
S01EA05	brimonidine	0,62	5	-7	315	5	-7
S01EB	Parasympathomimetics	0,11	11	-7	46	54	1
S01EB01	pilocarpine	0,11	11	-7	19	12	-7
S01EB09	acetylcholine	-	-	-	26	85	7
S01EC	Carbonic anhydrase inhibitors	2,37	3	16	1 264	3	7
S01EC03	dorzolamide	0,19	5	-1	134	5	-1
S01EC04	brinzolamide	1,91	3	4	681	3	4
S01EC54	brinzolamide, combinations	0,27	2	-	450	2	15
S01ED	Beta blocking agents	13,96	2	8	7 162	2	0
S01ED01	timolol	0,64	3	-4	282	3	-2
S01ED02	betaxolol	0,30	3	-3	79	3	-3
S01ED51	timolol, combinations	13,02	1	9	6 801	2	0
S01EE	Prostaglandin analogues	10,87	2	5	5 611	2	1
S01EE01	latanoprost	4,83	3	3	1 805	3	-4

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
S01EE03	bimatoprost	3,27	1	9	992	1	8
S01EE04	travoprost	0,95	3	-5	912	2	-5
S01EE05	tafluprost	1,82	1	6	1 903	1	6
S01F	MYDRIATICS AND CYCLOPLEGICS	-	-	-	631	64	11
S01FA	Anticholinergics	-	-	-	560	63	14
S01FA01	atropine	-	-	-	25	44	15
S01FA02	scopolamine	-	-	-	59	15	8
S01FA04	cyclopentolate	-	-	-	97	58	0
S01FA06	tropicamide	-	-	-	222	56	6
S01FA56	tropicamide, combinations	-	-	-	157	97	45
S01FB	Sympathomimetics excl. antiglaucoma preparations	-	-	-	71	73	-5
S01FB01	phenylephrine	-	-	-	71	73	-5
S01G	DECONGESTANTS AND ANTIALLERGICS	-	-	-	3 733	1	19
S01GA	Sympathomimetics used as decongestants	-	-	-	247	0	-4
S01GA02	tetryzoline	-	-	-	247	0	-4
S01GX	Other antiallergics	-	-	-	3 486	1	21
S01GX01	cromoglicic acid	-	-	-	2 527	1	19
S01GX02	levocabastine	-	-	-	206	0	29
S01GX05	lodoxamide	-	-	-	36	0	23
S01GX06	emedastine	-	-	-	30	0	35
S01GX07	azelastine	-	-	-	24	0	235
S01GX08	ketotifen	-	-	-	611	0	21
S01GX09	olopatadine	-	-	-	52	0	10
S01H	LOCAL ANESTHETICS	-	-	-	210	82	-2
S01HA	Local anesthetics	-	-	-	210	82	-2
S01HA02	oxybuprocaine	-	-	-	210	82	-2
S01J	DIAGNOSTIC AGENTS	-	-	-	198	60	-10
S01JA	Colouring agents	-	-	-	198	60	-10
S01JA01	fluorescein	-	-	-	19	99	-62
S01JA51	fluorescein, combinations	-	-	-	179	56	6
S01L	OCULAR VASCULAR DISORDER AGENTS	-	-	-	21 798	100	24
S01LA	Antineovascularisation agents	-	-	-	21 798	100	24
S01LA01	verteporfin	-	-	-	203	100	-27

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
S01LA04	ranibizumab	-	-	-	319	100	18
S01LA05	aflibercept	-	-	-	21 277	100	25
S01X	OTHER OPHTHALMOLOGICALS	-	-	-	6 715	3	-5
S01XA	Other ophthalmologicals	-	-	-	6 715	3	-5
S01XA02	retinol	-	-	-	408	3	9
S01XA18	ciclosporin	-	-	-	442	1	36
S01XA20	artificial tears and other indifferent preparations	-	-	-	5 861	3	-8
S01XA22	ocriplasmin	-	-	-	3	100	-
S02	OTOLOGICALS	-	-	-	1 776	2	7
S02A	ANTIINFECTIVES	-	-	-	693	2	12
S02AA	Antiinfectives	-	-	-	693	2	12
S02AA03	boric acid	-	-	-	664	2	12
S02AA15	ciprofloxacin	-	-	-	30	2	27
S02C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	-	-	-	861	3	8
S02CA	Corticosteroids and antiinfectives in combination	-	-	-	861	3	8
S02CA02	flumetasone and antiinfectives	-	-	-	1	8	-99
S02CA03	hydrocortisone and antiinfectives	-	-	-	624	4	18
S02CA05	fluocinolone acetonide and antiinfectives	-	-	-	236	2	19
S02D	OTHER OTOLOGICALS	-	-	-	222	1	-6
S02DA	Analgesics and anesthetics	-	-	-	222	1	-6
S02DA04	cinchocaine	-	-	-	222	1	-6
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	-	-	-	254	14	1
S03C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	-	-	-	254	14	1
S03CA	Corticosteroids and antiinfectives in combination	-	-	-	254	14	1
S03CA04	hydrocortisone and antiinfectives	-	-	-	254	14	1
<b>V</b>	<b>VARIOUS</b>	<b>0,16</b>	<b>41</b>	<b>6</b>	<b>35 360</b>	<b>90</b>	<b>0</b>
V01	ALLERGENS	-	-	-	2 369	56	11
V01A	ALLERGENS	-	-	-	2 369	56	11
V01AA	Allergen extracts	-	-	-	2 369	56	11
V01AA02	grass pollen	-	-	-	704	0	1
V01AA03	house dust mites	-	-	-	27	21	70



## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
V01AA05	tree pollen	-	-	-	1 443	79	15
V01AA07	insects	-	-	-	126	98	26
V01AA11	animals	-	-	-	69	77	8
V01AA20	various	-	-	-	1	57	18
V03	ALL OTHER THERAPEUTIC PRODUCTS	0,16	41	6	8 479	78	-19
V03A	ALL OTHER THERAPEUTIC PRODUCTS	0,16	41	6	8 479	78	-19
V03AB	Antidotes	-	-	-	4 717	97	-33
V03AB14	protamine	-	-	-	305	99	1
V03AB15	naloxone	-	-	-	85	90	-51
V03AB17	methylthioninium chloride	-	-	-	102	100	3
V03AB21	potassium iodide	-	-	-	177	45	-27
V03AB25	flumazenil	-	-	-	87	98	5
V03AB33	hydroxocobalamin	-	-	-	149	98	-24
V03AB34	fomepizole	-	-	-	122	100	-4
V03AB35	sugammadex	-	-	-	3 382	99	-39
V03AB37	idarucizumab	-	-	-	308	100	13
V03AC	Iron chelating agents	-	-	-	906	4	20
V03AC01	deferoxamine	-	-	-	10	87	18
V03AC02	deferiprone	-	-	-	8	20	-41
V03AC03	deferasirox	-	-	-	888	3	21
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia	0,11	18	1	943	17	2
V03AE01	polystyrene sulphonate	0,03	25	3	119	25	3
V03AE02	sevelamer	0,04	17	3	390	17	7
V03AE03	lanthanum carbonate	0,04	14	-2	434	14	-2
V03AE05	sucroferric oxyhydroxide	0,00	100	-	0	100	-
V03AF	Detoxifying agents for cytostatic treatment	0,05	95	18	1 913	95	11
V03AF01	mesna	-	-	-	487	100	24
V03AF02	dexrazoxane	0,00	100	93	307	100	106
V03AF03	calcium folinate	0,05	95	22	745	88	1
V03AF07	rasburicase	0,00	100	-19	318	100	-13
V03AF08	palifermin	0,00	100	-17	25	100	-17
V03AF10	sodium levofolinate	0,00	100	-48	31	100	-48
V04	DIAGNOSTIC AGENTS	-	-	-	995	85	11

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
V04C	OTHER DIAGNOSTIC AGENTS	-	-	-	995	85	11
V04CD	Tests for pituitary function	-	-	-	102	37	26
V04CD01	metyrapone	-	-	-	102	37	26
V04CF	Tuberculosis diagnostics	-	-	-	2	70	-53
V04CF01	tuberculin	-	-	-	2	70	-53
V04CL	Tests for allergic diseases	-	-	-	200	76	-11
V04CX	Other diagnostic agents	-	-	-	692	95	19
V06	GENERAL NUTRIENTS	-	-	-	0	29	-90
V06D	OTHER NUTRIENTS	-	-	-	0	29	-90
V06DD	Amino acids, incl. combinations with polypeptides	-	-	-	0	29	-90
V07	ALL OTHER NON-THERAPEUTIC PRODUCTS	-	-	-	3 230	95	8
V07A	ALL OTHER NON-THERAPEUTIC PRODUCTS	-	-	-	3 230	95	8
V07AB	Solvents and diluting agents, incl. irrigating solutions	-	-	-	3 230	95	8
V08	CONTRAST MEDIA	-	-	-	20 149	99	7
V08A	X-RAY CONTRAST MEDIA, IODINATED	-	-	-	15 102	100	7
V08AA	Watersoluble, nephrotropic, high osmolar X-ray contrast media	-	-	-	96	99	-22
V08AA01	diatrizoic acid	-	-	-	96	99	-22
V08AB	Watersoluble, nephrotropic, low osmolar X-ray contrast media	-	-	-	15 006	100	7
V08AB02	iohexol	-	-	-	12 104	100	12
V08AB03	ioxaglic acid	-	-	-	94	100	-77
V08AB07	ioversol	-	-	-	103	100	-74
V08AB09	iodixanol	-	-	-	1 190	98	11
V08AB10	iomeprol	-	-	-	1 515	99	10
V08B	X-RAY CONTRAST MEDIA, NON-IODINATED	-	-	-	26	100	-32
V08BA	Barium sulphate containing X-ray contrast media	-	-	-	26	100	-32
V08BA01	barium sulphate with suspending agents	-	-	-	26	100	-32
V08C	MAGNETIC RESONANCE IMAGING CONTRAST MEDIA	-	-	-	4 923	97	8
V08CA	Paramagnetic contrast media	-	-	-	4 923	97	8
V08CA01	gadopentetic acid	-	-	-	0	-	-100
V08CA02	gadoteric acid	-	-	-	4 599	97	9

## Drug consumption in current year (Period 201801 - 201812)

ATC code	Subgroup or chemical substance	DDD/1000 inhab./day	Hospital %	Change %	Wholesale price/1000 €	Hospital %	Change %
V08CA04	gadoteridol	-	-	-	128	99	36
V08CA08	gadobenic acid	-	-	-	3	100	-93
V08CA09	gadobutrol	-	-	-	26	100	-32
V08CA10	gadoxetic acid	-	-	-	167	99	15
V08D	ULTRASOUND CONTRAST MEDIA	-	-	-	98	100	-13
V08DA	Ultrasound contrast media	-	-	-	98	100	-13
V08DA01	microspheres of human albumin	-	-	-	2	100	100
V08DA05	sulphur hexafluoride	-	-	-	96	100	-14
V09	DIAGNOSTIC RADIOPHARMACEUTICALS	-	-	-	137	100	-40
V09C	RENAL SYSTEM	-	-	-	44	100	30
V09CA	Technetium (99mTc) compounds	-	-	-	44	100	30
V09CA03	technetium (99mTc) mertiatide	-	-	-	44	100	30
V09D	HEPATIC AND RETICULO ENDOTHELIAL SYSTEM	-	-	-	93	100	-12
V09DB	Technetium (99mTc), particles and colloids	-	-	-	93	100	-12
V09DB01	technetium (99mTc) nanocolloid	-	-	-	93	100	-12
V09E	RESPIRATORY SYSTEM	-	-	-	0	-	-100
V09EA	Technetium (99mTc), inhalants	-	-	-	0	-	-100
V09EA02	technetium (99mTc) technegas	-	-	-	0	-	-100
V09G	CARDIOVASCULAR SYSTEM	-	-	-	0	-	-100
V09GA	Technetium (99mTc) compounds	-	-	-	0	-	-100
V09GA01	technetium (99mTc) sestamibi	-	-	-	0	-	-100
V09GA04	technetium (99mTc) human albumin	-	-	-	0	-	-100
V09GA06	technetium (99mTc) stannous agent labelled cells	-	-	-	0	-	-100

Hospital % Sales to hospitals and other health care units as a proportion (%) of the wholesale value

Change % is compared with equal period in previous year